1
|
Georg Magalhães C, Ploeger Mansueli C, Manieri TM, Quintilio W, Garbuio A, de Jesus Marinho J, de Moraes JZ, Tsuruta LR, Moro AM. Impaired proliferation and migration of HUVEC and melanoma cells by human anti-FGF2 mAbs derived from a murine hybridoma by guided selection. Bioengineered 2023; 14:2252667. [PMID: 37661761 PMCID: PMC10478743 DOI: 10.1080/21655979.2023.2252667] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/08/2023] [Revised: 05/23/2023] [Accepted: 05/25/2023] [Indexed: 09/05/2023] Open
Abstract
Disadvantages of using murine monoclonal antibodies (mAb) in human therapy, such as immunogenicity response, led to the development of technologies to transform murine antibodies into human antibodies. The murine anti-FGF2 3F12E7 mAb was proposed as a promising agent to treat metastatic melanoma tumors; once it blocks the FGF2, responsible for playing a role in tumor growth, angiogenesis, and metastasis. Considering the therapeutic potential of anti-FGF2 3F12E7 mAb and its limited use in humans due to its origin, we used this antibody as the template for a guided selection humanization technique to obtain human anti-FGF2 mAbs. Three Fab libraries (murine, hybrid, and human) were constructed for humanization. The libraries were phage-displayed, and the panning was performed against recombinant human FGF2 (rFGF2). The selected human variable light and heavy chains were cloned into AbVec vectors for full-length IgG expression into HEK293-F cells. Surface plasmon resonance analyses showed binding to rFGF2 of seven mAbs out of 20 expressed. Assays performed with these mAbs resulted in two that showed proliferation reduction and cell migration attenuation of HUVEC and SK-Mel-28 melanoma cells. In-silico analyses predicted that these two human anti-FGF2 mAbs interact with FGF2 at a similar patch of residues than the chimeric anti-FGF2 antibody, comprehending a region within the heparin-binding domains of FGF2, essential for its function. These results are comparable to those achieved by the murine anti-FGF2 3F12E7 mAb and showed success in the humanization process and selection of two human mAbs with the potential to inhibit undesirable FGF2 roles.
Collapse
Affiliation(s)
| | | | | | - Wagner Quintilio
- Laboratory of Biopharmaceuticals, Butantan Institute, São Paulo, Brazil
| | - Angélica Garbuio
- Laboratory of Biopharmaceuticals, Butantan Institute, São Paulo, Brazil
| | | | - Jane Zveiter de Moraes
- Department of Biophysics, Escola Paulista de Medicina, Universidade Federal de São Paulo, São Paulo, Brazil
| | | | - Ana Maria Moro
- Laboratory of Biopharmaceuticals, Butantan Institute, São Paulo, Brazil
- CeRDI, Center for Research and Development in Immunobiologicals, Butantan Institute, São Paulo, Brazil
| |
Collapse
|
2
|
Servian CDP, Spadafora-Ferreira M, dos Anjos DCC, Guilarde AO, Gomes-Junior AR, Borges MASB, Masson LC, Silva JMM, de Lima MHA, Moraes BGN, Souza SM, Xavier LE, de Oliveira DCA, Batalha-Carvalho JV, Moro AM, Bocca AL, Pfrimer IAH, Costa NL, Feres VCDR, Fiaccadori FS, Souza M, Gardinassi LG, Durigon EL, Romão PRT, Jorge SAC, Coelho V, Botosso VF, Fonseca SG. Distinct anti-NP, anti-RBD and anti-Spike antibody profiles discriminate death from survival in COVID-19. Front Immunol 2023; 14:1206979. [PMID: 37876932 PMCID: PMC10591157 DOI: 10.3389/fimmu.2023.1206979] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/16/2023] [Accepted: 09/04/2023] [Indexed: 10/26/2023] Open
Abstract
Introduction Infection by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) induces rapid production of IgM, IgA, and IgG antibodies directed to multiple viral antigens that may have impact diverse clinical outcomes. Methods We evaluated IgM, IgA, and IgG antibodies directed to the nucleocapsid (NP), IgA and IgG to the Spike protein and to the receptor-binding domain (RBD), and the presence of neutralizing antibodies (nAb), in a cohort of unvaccinated SARS-CoV-2 infected individuals, in the first 30 days of post-symptom onset (PSO) (T1). Results This study included 193 coronavirus disease 2019 (COVID-19) participants classified as mild, moderate, severe, critical, and fatal and 27 uninfected controls. In T1, we identified differential antibody profiles associated with distinct clinical presentation. The mild group presented lower levels of anti-NP IgG, and IgA (vs moderate and severe), anti-NP IgM (vs severe, critical and fatal), anti-Spike IgA (vs severe and fatal), and anti-RBD IgG (vs severe). The moderate group presented higher levels of anti-RBD IgA, comparing with severe group. The severe group presented higher levels of anti-NP IgA (vs mild and fatal) and anti-RBD IgG (vs mild and moderate). The fatal group presented higher levels of anti-NP IgM and anti-Spike IgA (vs mild), but lower levels of anti-NP IgA (vs severe). The levels of nAb was lower just in mild group compared to severe, critical, and fatal groups, moreover, no difference was observed among the more severe groups. In addition, we studied 82 convalescent individuals, between 31 days to 6 months (T2) or more than 6 months (T3), PSO, those: 12 mild, 26 moderate, and 46 severe plus critical. The longitudinal analyzes, for the severe plus critical group showed lower levels of anti-NP IgG, IgA and IgM, anti-Spike IgA in relation T3. The follow-up in the fatal group, reveals that the levels of anti-spike IgG increased, while anti-NP IgM levels was decreased along the time in severe/critical and fatal as well as anti-NP IgG and IgA in several/critical groups. Discussion In summary, the anti-NP IgA and IgG lower levels and the higher levels of anti-RBD and anti-Spike IgA in fatal compared to survival group of individuals admitted to the intensive care unit (ICU). Collectively, our data discriminate death from survival, suggesting that anti-RBD IgA and anti-Spike IgA may play some deleterious effect, in contrast with the potentially protective effect of anti-NP IgA and IgG in the survival group.
Collapse
Affiliation(s)
- Carolina do Prado Servian
- Departamento de Biociências e Tecnologia, Instituto de Patologia Tropical e Saúde Pública, Universidade Federal de Goiás, Goiânia, GO, Brazil
| | | | - Déborah Carolina Carvalho dos Anjos
- Departamento de Biociências e Tecnologia, Instituto de Patologia Tropical e Saúde Pública, Universidade Federal de Goiás, Goiânia, GO, Brazil
| | - Adriana Oliveira Guilarde
- Departamento de Patologia Tropical e Dermatologia, Instituto de Patologia Tropical e Saúde Pública, Universidade Federal de Goiás, Goiânia, GO, Brazil
- Hospital das Clínicas, Faculdade de Medicina, Universidade Federal de Goiás, Goiânia, GO, Brazil
| | - Antonio Roberto Gomes-Junior
- Departamento de Biociências e Tecnologia, Instituto de Patologia Tropical e Saúde Pública, Universidade Federal de Goiás, Goiânia, GO, Brazil
| | - Moara Alves Santa Bárbara Borges
- Departamento de Patologia Tropical e Dermatologia, Instituto de Patologia Tropical e Saúde Pública, Universidade Federal de Goiás, Goiânia, GO, Brazil
- Hospital das Clínicas, Faculdade de Medicina, Universidade Federal de Goiás, Goiânia, GO, Brazil
| | - Letícia Carrijo Masson
- Departamento de Biociências e Tecnologia, Instituto de Patologia Tropical e Saúde Pública, Universidade Federal de Goiás, Goiânia, GO, Brazil
| | - João Marcos Maia Silva
- Departamento de Biociências e Tecnologia, Instituto de Patologia Tropical e Saúde Pública, Universidade Federal de Goiás, Goiânia, GO, Brazil
| | | | | | - Sueli Meira Souza
- Laboratório Prof Margarida Dobler Komma, Instituto de Patologia Tropical e Saúde Pública, Universidade Federal de Goiás, Goiânia, GO, Brazil
| | - Luiz Eterno Xavier
- Hospital das Clínicas, Faculdade de Medicina, Universidade Federal de Goiás, Goiânia, GO, Brazil
| | | | | | - Ana Maria Moro
- Laboratório de Biofármacos, Instituto Butantan, São Paulo, SP, Brazil
- Instituto de Investigação em Imunologia – Instituto Nacional de Ciências e Tecnologia (III-INCT), São Paulo, SP, Brazil
| | - Anamélia Lorenzetti Bocca
- Departamento de Biologia Celular, Instituto de Biologia, Universidade de Brasília, Brasília, DF, Brazil
| | | | - Nádia Lago Costa
- Faculdade de Odontologia, Universidade Federal de Goiás, Goiânia, GO, Brazil
| | | | - Fabiola Souza Fiaccadori
- Departamento de Biociências e Tecnologia, Instituto de Patologia Tropical e Saúde Pública, Universidade Federal de Goiás, Goiânia, GO, Brazil
| | - Menira Souza
- Departamento de Biociências e Tecnologia, Instituto de Patologia Tropical e Saúde Pública, Universidade Federal de Goiás, Goiânia, GO, Brazil
| | - Luiz Gustavo Gardinassi
- Departamento de Biociências e Tecnologia, Instituto de Patologia Tropical e Saúde Pública, Universidade Federal de Goiás, Goiânia, GO, Brazil
| | - Edison Luiz Durigon
- Departamento de Microbiologia, Instituto de Ciências Biomédicas, Universidade de São Paulo, São Paulo, SP, Brazil
| | - Pedro Roosevelt Torres Romão
- Laboratório de Imunologia Celular e Molecular, Programa de Pós-Graduação em Ciências da Saúde, Programa de Pós-Graduação em Biociências, Universidade Federal de Ciências da Saúde de Porto Alegre, Porto Alegre, RS, Brazil
| | | | - Verônica Coelho
- Instituto de Investigação em Imunologia – Instituto Nacional de Ciências e Tecnologia (III-INCT), São Paulo, SP, Brazil
- Laboratório de Imunologia, Instituto do Coração (InCor), Universidade de São Paulo, Faculdade de Medicina, São Paulo, SP, Brazil
- Laboratório de Histocompatibilidade e Imunidade Celular, Hospital das Clínicas Hospital da Clínicas, Faculdade de Medicina, Universidade de São Paulo (HCFMUSP), São Paulo, SP, Brazil
| | | | - Simone Gonçalves Fonseca
- Departamento de Biociências e Tecnologia, Instituto de Patologia Tropical e Saúde Pública, Universidade Federal de Goiás, Goiânia, GO, Brazil
- Instituto de Investigação em Imunologia – Instituto Nacional de Ciências e Tecnologia (III-INCT), São Paulo, SP, Brazil
| |
Collapse
|
3
|
Coelho FF, da Silva MA, Lopes TB, Polatto JM, de Castro NS, Andrade LAF, Lourenço KL, Sato HI, de Carvalho AF, Coelho HP, Bagno FF, Luz D, Viala VL, Cattony PQ, Melo BDS, Moro AM, Quintilio W, Barbosa AP, Bomfim CG, Soares CP, Guzzo CR, Fonseca FG, Durigon EL, Gazzinelli RT, Ribeiro Teixeira SM, Piazza RMF, Fernandes AP. SARS-CoV-2 Rapid Antigen Test Based on a New Anti-Nucleocapsid Protein Monoclonal Antibody: Development and Real-Time Validation. Microorganisms 2023; 11:2422. [PMID: 37894080 PMCID: PMC10608853 DOI: 10.3390/microorganisms11102422] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/12/2023] [Revised: 08/27/2023] [Accepted: 09/01/2023] [Indexed: 10/29/2023] Open
Abstract
SARS-CoV-2 diagnostic tests have become an important tool for pandemic control. Among the alternatives for COVID-19 diagnosis, antigen rapid diagnostic tests (Ag-RDT) are very convenient and widely used. However, as SARS-CoV-2 variants may continuously emerge, the replacement of tests and reagents may be required to maintain the sensitivity of Ag-RDTs. Here, we describe the development and validation of an Ag-RDT during an outbreak of the Omicron variant, including the characterization of a new monoclonal antibody (anti-DTC-N 1B3 mAb) that recognizes the Nucleocapsid protein (N). The anti-DTC-N 1B3 mAb recognized the sequence TFPPTEPKKDKKK located at the C-terminus of the N protein of main SARS-CoV-2 variants of concern. Accordingly, the Ag-RDT prototypes using the anti-DTC-N 1B3 mAB detected all the SARS-CoV-2 variants-Wuhan, Alpha, Gamma, Delta, P2 and Omicron. The performance of the best prototype (sensitivity of 95.2% for samples with Ct ≤ 25; specificity of 98.3% and overall accuracy of 85.0%) met the WHO recommendations. Moreover, results from a patients' follow-up study indicated that, if performed within the first three days after onset of symptoms, the Ag-RDT displayed 100% sensitivity. Thus, the new mAb and the Ag-RDT developed herein may constitute alternative tools for COVID-19 point-of-care diagnosis and epidemiological surveillance.
Collapse
Affiliation(s)
- Fabiana Fioravante Coelho
- Faculdade de Farmácia, Universidade Federal de Minas Gerais, Belo Horizonte 31270-901, Brazil;
- Hospital da Polícia Militar de Minas Gerais, Polícia Militar de Minas Gerais, Belo Horizonte 30110-013, Brazil
- Centro de Tecnologia em Vacinas, Universidade Federal de Minas Gerais, Belo Horizonte 31310-260, Brazil; (T.B.L.); (N.S.d.C.); (L.A.F.A.); (K.L.L.); (H.I.S.); (A.F.d.C.); (H.P.C.); (F.F.B.); (F.G.F.); (R.T.G.); (S.M.R.T.)
| | - Miriam Aparecida da Silva
- Instituto Butantan, São Paulo 05503-900, Brazil; (M.A.d.S.); (J.M.P.); (D.L.); (V.L.V.); (P.Q.C.); (B.d.S.M.); (A.M.M.); (W.Q.); (A.P.B.); (R.M.F.P.)
| | - Thiciany Blener Lopes
- Centro de Tecnologia em Vacinas, Universidade Federal de Minas Gerais, Belo Horizonte 31310-260, Brazil; (T.B.L.); (N.S.d.C.); (L.A.F.A.); (K.L.L.); (H.I.S.); (A.F.d.C.); (H.P.C.); (F.F.B.); (F.G.F.); (R.T.G.); (S.M.R.T.)
| | - Juliana Moutinho Polatto
- Instituto Butantan, São Paulo 05503-900, Brazil; (M.A.d.S.); (J.M.P.); (D.L.); (V.L.V.); (P.Q.C.); (B.d.S.M.); (A.M.M.); (W.Q.); (A.P.B.); (R.M.F.P.)
| | - Natália Salazar de Castro
- Centro de Tecnologia em Vacinas, Universidade Federal de Minas Gerais, Belo Horizonte 31310-260, Brazil; (T.B.L.); (N.S.d.C.); (L.A.F.A.); (K.L.L.); (H.I.S.); (A.F.d.C.); (H.P.C.); (F.F.B.); (F.G.F.); (R.T.G.); (S.M.R.T.)
| | - Luis Adan Flores Andrade
- Centro de Tecnologia em Vacinas, Universidade Federal de Minas Gerais, Belo Horizonte 31310-260, Brazil; (T.B.L.); (N.S.d.C.); (L.A.F.A.); (K.L.L.); (H.I.S.); (A.F.d.C.); (H.P.C.); (F.F.B.); (F.G.F.); (R.T.G.); (S.M.R.T.)
| | - Karine Lima Lourenço
- Centro de Tecnologia em Vacinas, Universidade Federal de Minas Gerais, Belo Horizonte 31310-260, Brazil; (T.B.L.); (N.S.d.C.); (L.A.F.A.); (K.L.L.); (H.I.S.); (A.F.d.C.); (H.P.C.); (F.F.B.); (F.G.F.); (R.T.G.); (S.M.R.T.)
| | - Hugo Itaru Sato
- Centro de Tecnologia em Vacinas, Universidade Federal de Minas Gerais, Belo Horizonte 31310-260, Brazil; (T.B.L.); (N.S.d.C.); (L.A.F.A.); (K.L.L.); (H.I.S.); (A.F.d.C.); (H.P.C.); (F.F.B.); (F.G.F.); (R.T.G.); (S.M.R.T.)
| | - Alex Fiorini de Carvalho
- Centro de Tecnologia em Vacinas, Universidade Federal de Minas Gerais, Belo Horizonte 31310-260, Brazil; (T.B.L.); (N.S.d.C.); (L.A.F.A.); (K.L.L.); (H.I.S.); (A.F.d.C.); (H.P.C.); (F.F.B.); (F.G.F.); (R.T.G.); (S.M.R.T.)
| | - Helena Perez Coelho
- Centro de Tecnologia em Vacinas, Universidade Federal de Minas Gerais, Belo Horizonte 31310-260, Brazil; (T.B.L.); (N.S.d.C.); (L.A.F.A.); (K.L.L.); (H.I.S.); (A.F.d.C.); (H.P.C.); (F.F.B.); (F.G.F.); (R.T.G.); (S.M.R.T.)
| | - Flávia Fonseca Bagno
- Centro de Tecnologia em Vacinas, Universidade Federal de Minas Gerais, Belo Horizonte 31310-260, Brazil; (T.B.L.); (N.S.d.C.); (L.A.F.A.); (K.L.L.); (H.I.S.); (A.F.d.C.); (H.P.C.); (F.F.B.); (F.G.F.); (R.T.G.); (S.M.R.T.)
| | - Daniela Luz
- Instituto Butantan, São Paulo 05503-900, Brazil; (M.A.d.S.); (J.M.P.); (D.L.); (V.L.V.); (P.Q.C.); (B.d.S.M.); (A.M.M.); (W.Q.); (A.P.B.); (R.M.F.P.)
| | - Vincent Louis Viala
- Instituto Butantan, São Paulo 05503-900, Brazil; (M.A.d.S.); (J.M.P.); (D.L.); (V.L.V.); (P.Q.C.); (B.d.S.M.); (A.M.M.); (W.Q.); (A.P.B.); (R.M.F.P.)
| | - Pedro Queiroz Cattony
- Instituto Butantan, São Paulo 05503-900, Brazil; (M.A.d.S.); (J.M.P.); (D.L.); (V.L.V.); (P.Q.C.); (B.d.S.M.); (A.M.M.); (W.Q.); (A.P.B.); (R.M.F.P.)
| | - Bruna de Sousa Melo
- Instituto Butantan, São Paulo 05503-900, Brazil; (M.A.d.S.); (J.M.P.); (D.L.); (V.L.V.); (P.Q.C.); (B.d.S.M.); (A.M.M.); (W.Q.); (A.P.B.); (R.M.F.P.)
| | - Ana Maria Moro
- Instituto Butantan, São Paulo 05503-900, Brazil; (M.A.d.S.); (J.M.P.); (D.L.); (V.L.V.); (P.Q.C.); (B.d.S.M.); (A.M.M.); (W.Q.); (A.P.B.); (R.M.F.P.)
| | - Wagner Quintilio
- Instituto Butantan, São Paulo 05503-900, Brazil; (M.A.d.S.); (J.M.P.); (D.L.); (V.L.V.); (P.Q.C.); (B.d.S.M.); (A.M.M.); (W.Q.); (A.P.B.); (R.M.F.P.)
| | - Ana Paula Barbosa
- Instituto Butantan, São Paulo 05503-900, Brazil; (M.A.d.S.); (J.M.P.); (D.L.); (V.L.V.); (P.Q.C.); (B.d.S.M.); (A.M.M.); (W.Q.); (A.P.B.); (R.M.F.P.)
| | - Camila Gasque Bomfim
- Department of Microbiology, Institute of Biomedical Sciences, University of São Paulo, São Paulo 05508-900, Brazil; (C.G.B.); (C.P.S.); (C.R.G.); (E.L.D.)
| | - Camila Pereira Soares
- Department of Microbiology, Institute of Biomedical Sciences, University of São Paulo, São Paulo 05508-900, Brazil; (C.G.B.); (C.P.S.); (C.R.G.); (E.L.D.)
| | - Cristiane Rodrigues Guzzo
- Department of Microbiology, Institute of Biomedical Sciences, University of São Paulo, São Paulo 05508-900, Brazil; (C.G.B.); (C.P.S.); (C.R.G.); (E.L.D.)
| | - Flavio Guimarães Fonseca
- Centro de Tecnologia em Vacinas, Universidade Federal de Minas Gerais, Belo Horizonte 31310-260, Brazil; (T.B.L.); (N.S.d.C.); (L.A.F.A.); (K.L.L.); (H.I.S.); (A.F.d.C.); (H.P.C.); (F.F.B.); (F.G.F.); (R.T.G.); (S.M.R.T.)
| | - Edison Luiz Durigon
- Department of Microbiology, Institute of Biomedical Sciences, University of São Paulo, São Paulo 05508-900, Brazil; (C.G.B.); (C.P.S.); (C.R.G.); (E.L.D.)
| | - Ricardo Tostes Gazzinelli
- Centro de Tecnologia em Vacinas, Universidade Federal de Minas Gerais, Belo Horizonte 31310-260, Brazil; (T.B.L.); (N.S.d.C.); (L.A.F.A.); (K.L.L.); (H.I.S.); (A.F.d.C.); (H.P.C.); (F.F.B.); (F.G.F.); (R.T.G.); (S.M.R.T.)
| | - Santuza M. Ribeiro Teixeira
- Centro de Tecnologia em Vacinas, Universidade Federal de Minas Gerais, Belo Horizonte 31310-260, Brazil; (T.B.L.); (N.S.d.C.); (L.A.F.A.); (K.L.L.); (H.I.S.); (A.F.d.C.); (H.P.C.); (F.F.B.); (F.G.F.); (R.T.G.); (S.M.R.T.)
| | - Roxane Maria Fontes Piazza
- Instituto Butantan, São Paulo 05503-900, Brazil; (M.A.d.S.); (J.M.P.); (D.L.); (V.L.V.); (P.Q.C.); (B.d.S.M.); (A.M.M.); (W.Q.); (A.P.B.); (R.M.F.P.)
| | - Ana Paula Fernandes
- Faculdade de Farmácia, Universidade Federal de Minas Gerais, Belo Horizonte 31270-901, Brazil;
- Centro de Tecnologia em Vacinas, Universidade Federal de Minas Gerais, Belo Horizonte 31310-260, Brazil; (T.B.L.); (N.S.d.C.); (L.A.F.A.); (K.L.L.); (H.I.S.); (A.F.d.C.); (H.P.C.); (F.F.B.); (F.G.F.); (R.T.G.); (S.M.R.T.)
| |
Collapse
|
4
|
Sivelle C, Sierocki R, Lesparre Y, Lomet A, Quintilio W, Dubois S, Correia E, Moro AM, Maillère B, Nozach H. Combining deep mutational scanning to heatmap of HLA class II binding of immunogenic sequences to preserve functionality and mitigate predicted immunogenicity. Front Immunol 2023; 14:1197919. [PMID: 37575221 PMCID: PMC10416631 DOI: 10.3389/fimmu.2023.1197919] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/03/2023] [Accepted: 07/10/2023] [Indexed: 08/15/2023] Open
Abstract
Removal of CD4 T cell epitopes from therapeutic antibody sequences is expected to mitigate their potential immunogenicity, but its application is complicated by the location of their T cell epitopes, which mainly overlap with complementarity-determining regions. We therefore evaluated the flexibility of antibody sequences to reduce the predicted affinity of corresponding peptides for HLA II molecules and to maintain antibody binding to its target in order to guide antibody engineering for mitigation of predicted immunogenicity. Permissive substitutions to reduce affinity of peptides for HLA II molecules were identified by establishing a heatmap of HLA class II binding using T-cell epitope prediction tools, while permissive substitutions preserving binding to the target were identified by means of deep mutational scanning and yeast surface display. Combinatorial libraries were then designed to identify active clones. Applied to adalimumab, an anti-TNFα human antibody, this approach identified 200 mutants with a lower HLA binding score than adalimumab. Three mutants were produced as full-length antibodies and showed a higher affinity for TNFα and neutralization ability than adalimumab. This study also sheds light on the permissiveness of antibody sequences with regard to functionality and predicted T cell epitope content.
Collapse
Affiliation(s)
- Coline Sivelle
- Université de Paris-Saclay, CEA, INRAE, Département Médicaments et Technologies pour la Santé, SIMoS, Gif-sur-Yvette, France
| | - Raphael Sierocki
- Université de Paris-Saclay, CEA, INRAE, Département Médicaments et Technologies pour la Santé, SIMoS, Gif-sur-Yvette, France
- Deeptope SAS, Orsay, France
| | | | - Aurore Lomet
- CEA List, Université Paris-Saclay, Palaiseau, France
| | - Wagner Quintilio
- Biopharmaceuticals Laboratory, Butantan Institute, Sao Paulo, Brazil
| | - Steven Dubois
- Université de Paris-Saclay, CEA, INRAE, Département Médicaments et Technologies pour la Santé, SIMoS, Gif-sur-Yvette, France
| | - Evelyne Correia
- Université de Paris-Saclay, CEA, INRAE, Département Médicaments et Technologies pour la Santé, SIMoS, Gif-sur-Yvette, France
| | - Ana Maria Moro
- Biopharmaceuticals Laboratory, Butantan Institute, Sao Paulo, Brazil
| | - Bernard Maillère
- Université de Paris-Saclay, CEA, INRAE, Département Médicaments et Technologies pour la Santé, SIMoS, Gif-sur-Yvette, France
| | - Hervé Nozach
- Université de Paris-Saclay, CEA, INRAE, Département Médicaments et Technologies pour la Santé, SIMoS, Gif-sur-Yvette, France
| |
Collapse
|
5
|
Masson LC, Servian CDP, Jardim VH, Dos Anjos D, Dorta ML, Batalha-Carvalho JV, Moro AM, Romão PRT, Souza M, Fiaccadori FS, Fonseca SG. Heterologous Booster with BNT162b2 Induced High Specific Antibody Levels in CoronaVac Vaccinees. Vaccines (Basel) 2023; 11:1183. [PMID: 37514999 PMCID: PMC10383528 DOI: 10.3390/vaccines11071183] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/21/2023] [Revised: 06/21/2023] [Accepted: 06/25/2023] [Indexed: 07/30/2023] Open
Abstract
Immune responses after COVID-19 vaccination should be evaluated in different populations around the world. This study compared antibody responses induced by ChAdOx1 nCoV-19, CoronaVac, and BNT162b2 vaccines. Blood samples from vaccinees were collected pre- and post-vaccinations with the second and third doses. The study enrolled 78 vaccinees, of whom 62.8% were women, with the following median ages: 26 years-ChAdOx1 nCoV-19; 40 years-CoronaVac; 30 years-BNT162b2. Serum samples were quantified for anti-RBD IgG and anti-RBD IgA and anti-spike IgG by ELISA. After two vaccine doses, BNT162b2 vaccinees produced higher levels of anti-RBD IgA and IgG, and anti-spike IgG compared to ChAdOx1 nCoV-19 and CoronaVac vaccinees. The third dose booster with BNT162b2 induced higher levels of anti-RBD IgA and IgG, and anti-spike IgG in CoronaVac vaccinees. Individuals who reported a SARS-CoV-2 infection before or during the study had higher anti-RBD IgA and IgG production. In conclusion, two doses of the studied vaccines induced detectable levels of anti-RBD IgA and IgG and anti-spike IgG in vaccinees. The heterologous booster with BNT162b2 increased anti-RBD IgA and IgG and anti-spike IgG levels in CoronaVac vaccinees and anti-RBD IgA levels in ChAdOx1 nCoV-19 vaccinees. Furthermore, SARS-CoV-2 infection induced higher anti-RBD IgA and IgG levels in CoronaVac vaccinees.
Collapse
Affiliation(s)
- Letícia Carrijo Masson
- Departamento de Biociências e Tecnologia, Instituto de Patologia Tropical e Saúde Pública, Universidade Federal de Goiás, Goiânia 74605-050, GO, Brazil
| | - Carolina do Prado Servian
- Departamento de Biociências e Tecnologia, Instituto de Patologia Tropical e Saúde Pública, Universidade Federal de Goiás, Goiânia 74605-050, GO, Brazil
| | - Vitor Hugo Jardim
- Departamento de Biociências e Tecnologia, Instituto de Patologia Tropical e Saúde Pública, Universidade Federal de Goiás, Goiânia 74605-050, GO, Brazil
| | - Déborah Dos Anjos
- Departamento de Biociências e Tecnologia, Instituto de Patologia Tropical e Saúde Pública, Universidade Federal de Goiás, Goiânia 74605-050, GO, Brazil
| | - Miriam Leandro Dorta
- Departamento de Biociências e Tecnologia, Instituto de Patologia Tropical e Saúde Pública, Universidade Federal de Goiás, Goiânia 74605-050, GO, Brazil
| | | | - Ana Maria Moro
- Laboratório de Biofármacos, Instituto Butantan, São Paulo 05503-900, SP, Brazil
- Instituto de Investigação em Imunologia, Instituto Nacional de Ciência e Tecnologia (iii-INCT), Goiânia 74605-050, GO, Brazil
| | - Pedro Roosevelt Torres Romão
- Laboratório de Imunologia Celular e Molecular, Programa de Pós-Graduação em Ciências da Saúde, Programa de Pós-Graduação em Biociências, Universidade Federal de Ciências da Saúde de Porto Alegre, Porto Alegre 90050-170, RS, Brazil
| | - Menira Souza
- Departamento de Biociências e Tecnologia, Instituto de Patologia Tropical e Saúde Pública, Universidade Federal de Goiás, Goiânia 74605-050, GO, Brazil
| | - Fabiola Souza Fiaccadori
- Departamento de Biociências e Tecnologia, Instituto de Patologia Tropical e Saúde Pública, Universidade Federal de Goiás, Goiânia 74605-050, GO, Brazil
| | - Simone Gonçalves Fonseca
- Departamento de Biociências e Tecnologia, Instituto de Patologia Tropical e Saúde Pública, Universidade Federal de Goiás, Goiânia 74605-050, GO, Brazil
- Instituto de Investigação em Imunologia, Instituto Nacional de Ciência e Tecnologia (iii-INCT), Goiânia 74605-050, GO, Brazil
| |
Collapse
|
6
|
Manieri TM, Takata DY, Targino RC, Quintilio W, Batalha-Carvalho JV, da Silva CML, Moro AM. Characterization of Neutralizing Human Anti-Tetanus Monoclonal Antibodies Produced by Stable Cell Lines. Pharmaceutics 2022; 14:1985. [PMID: 36297421 PMCID: PMC9611486 DOI: 10.3390/pharmaceutics14101985] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/13/2022] [Revised: 09/14/2022] [Accepted: 09/16/2022] [Indexed: 10/12/2023] Open
Abstract
Tetanus toxin (TeNT) is produced by C. tetani, a spore-forming bacillus broadly spread in the environment. Although an inexpensive and safe vaccine is available, tetanus persists because of a lack of booster shots and variable responses to vaccines due to immunocompromised status or age-decreased immune surveillance. Tetanus is most prevalent in low- and medium-income countries, where it remains a health problem. Neutralizing monoclonal antibodies (mAbs) can prevent the severity of illness and death caused by C. tetani infection. We identified a panel of mAbs that bind to TeNT, some of which were investigated in a preclinical assay, showing that a trio of mAbs that bind to different sites of TeNT can neutralize the toxin and prevent symptoms and death in mice. We also identified two mAbs that can impair the binding of TeNT to the GT1b ganglioside receptor in neurons. In this work, to generate a series of cell lines, we constructed vectors containing sequences encoding heavy and light constant regions that can receive the paired variable regions resulting from PCRs of human B cells. In this way, we generated stable cell lines for five mAbs and compared and characterized the antibody produced in large quantities, enabling the characterization experiments. We present the results regarding the cell growth and viability in a fed-batch culture, titer measurement, and specific productivity estimation. The affinity of purified mAbs was analyzed by kinetics and under steady-state conditions, as three mAbs could not dissociate from TeNT within 36,000 s. The binding of mAbs to TeNT was confirmed by ELISA and inhibition of toxin binding to GT1b. The use of the mAbs mixture confirmed the individual mAb contribution to inhibition. We also analyzed the binding of mAbs to FcγR by surface plasmon resonance (SPR) and the glycan composition. Molecular docking analyses showed the binding site of an anti-tetanus mAb.
Collapse
Affiliation(s)
- Tania Maria Manieri
- Biopharmaceuticals Laboratory, Butantan Institute, Sao Paulo 05503-900, Brazil
| | - Daniela Yumi Takata
- Biopharmaceuticals Laboratory, Butantan Institute, Sao Paulo 05503-900, Brazil
- Interunits Graduate Program in Biotechnology, University of Sao Paulo, Sao Paulo 05508-270, Brazil
| | | | - Wagner Quintilio
- Biopharmaceuticals Laboratory, Butantan Institute, Sao Paulo 05503-900, Brazil
| | - João Victor Batalha-Carvalho
- Biopharmaceuticals Laboratory, Butantan Institute, Sao Paulo 05503-900, Brazil
- Graduate Program in Immunology, University of Sao Paulo, Sao Paulo 05508-270, Brazil
| | | | - Ana Maria Moro
- Biopharmaceuticals Laboratory, Butantan Institute, Sao Paulo 05503-900, Brazil
- Center for Research and Development in Immunobiologicals (CeRDI), Butantan Institute, Sao Paulo 05503-900, Brazil
- National Institute for Science and Technology (INCT/iii), University of Sao Paulo, Sao Paulo 05403-900, Brazil
| |
Collapse
|
7
|
Andrade SA, Batalha-Carvalho JV, Curi R, Wen FH, Covas DT, Chudzinski-Tavassi AM, Moro AM. Equine Anti-SARS-CoV-2 Serum (ECIG) Binds to Mutated RBDs and N Proteins of Variants of Concern and Inhibits the Binding of RBDs to ACE-2 Receptor. Front Immunol 2022; 13:871874. [PMID: 35898497 PMCID: PMC9310548 DOI: 10.3389/fimmu.2022.871874] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/08/2022] [Accepted: 06/07/2022] [Indexed: 11/13/2022] Open
Abstract
The COVID-19 pandemic caused by the severe acute syndrome virus 2 (SARS-CoV-2) has been around since November 2019. As of early June 2022, more than 527 million cases were diagnosed, with more than 6.0 million deaths due to this disease. Coronaviruses accumulate mutations and generate greater diversity through recombination when variants with different mutations infect the same host. Consequently, this virus is predisposed to constant and diverse mutations. The SARS-CoV-2 variants of concern/interest (VOCs/VOIs) such as Alpha (B.1.1.7), Beta (B.1.351), Gamma (B.1.1.28/P.1), Delta (B.1.617.2), and Omicron (B.1.1.529) have quickly spread across the world. These VOCs and VOIs have accumulated mutations within the spike protein receptor-binding domain (RBD) which interacts with the angiotensin-2 converting enzyme (ACE-2) receptor, increasing cell entry and infection. The RBD region is the main target for neutralizing antibodies; however, other notable mutations have been reported to enhance COVID-19 infectivity and lethality. Considering the urgent need for alternative therapies against this virus, an anti-SARS-CoV-2 equine immunoglobulin F(ab’)2, called ECIG, was developed by the Butantan Institute using the whole gamma-irradiated SARS-CoV-2 virus. Surface plasmon resonance experiments revealed that ECIG binds to wild-type and mutated RBD, S1+S2 domains, and nucleocapsid proteins of known VOCs, including Alpha, Gamma, Beta, Delta, Delta Plus, and Omicron. Additionally, it was observed that ECIG attenuates the binding of RBD (wild-type, Beta, and Omicron) to human ACE-2, suggesting that it could prevent viral entry into the host cell. Furthermore, the ability to concomitantly bind to the wild-type and mutated nucleocapsid protein likely enhances its neutralizing activity of SARS-CoV-2. We postulate that ECIG benefits COVID-19 patients by reducing the infectivity of the original virus and existing variants and may be effective against future ones. Impacting the course of the disease, mainly in the more vulnerable, reduces infection time and limits the appearance of new variants by new recombination.
Collapse
Affiliation(s)
| | | | - Rui Curi
- Cruzeiro do Sul University, São Paulo, Brazil
- Immunobiological Production Section, Bioindustrial Center, Butantan Institute, São Paulo, Brazil
| | - Fan Hui Wen
- Immunobiological Production Section, Bioindustrial Center, Butantan Institute, São Paulo, Brazil
| | | | - Ana Marisa Chudzinski-Tavassi
- Center of Excellence in New Target Discovery (CENTD), Instituto Butantan, São Paulo, Brazil
- Innovation and Development Laboratory, Instituto Butantan, São Paulo, Brazil
- *Correspondence: Ana Marisa Chudzinski-Tavassi, ; Ana Maria Moro,
| | - Ana Maria Moro
- Biopharmaceuticals Laboratory, Instituto Butantan, São Paulo, Brazil
- Center for Research and Development in Immunobiologicals (CeRDI), Instituto Butantan, São Paulo, Brazil
- *Correspondence: Ana Marisa Chudzinski-Tavassi, ; Ana Maria Moro,
| |
Collapse
|
8
|
Tsuruta LR, Moro AM, Tambourgi DV, Sant’Anna OA. Oral Tolerance Induction by Bothrops jararaca Venom in a Murine Model and Cross-Reactivity with Toxins of Other Snake Venoms. Toxins (Basel) 2021; 13:865. [PMID: 34941703 PMCID: PMC8706775 DOI: 10.3390/toxins13120865] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/15/2021] [Revised: 11/23/2021] [Accepted: 11/30/2021] [Indexed: 01/06/2023] Open
Abstract
Oral tolerance is defined as a specific suppression of cellular and humoral immune responses to a particular antigen through prior oral administration of an antigen. It has unique immunological importance since it is a natural and continuous event driven by external antigens. It is characterized by low levels of IgG in the serum of animals after immunization with the antigen. There is no report of induction of oral tolerance to Bothrops jararaca venom. Here, we induced oral tolerance to B. jararaca venom in BALB/c mice and evaluated the specific tolerance and cross-reactivity with the toxins of other Bothrops species after immunization with the snake venoms adsorbed to/encapsulated in nanostructured SBA-15 silica. Animals that received a high dose of B. jararaca venom (1.8 mg) orally responded by showing antibody titers similar to those of immunized animals. On the other hand, mice tolerized orally with three doses of 1 µg of B. jararaca venom showed low antibody titers. In animals that received a low dose of B. jararaca venom and were immunized with B. atrox or B. jararacussu venom, tolerance was null or only partial. Immunoblot analysis against the venom of different Bothrops species provided details about the main tolerogenic epitopes and clearly showed a difference compared to antiserum of immunized animals.
Collapse
Affiliation(s)
- Lilian Rumi Tsuruta
- Biopharmaceuticals Laboratory, Butantan Institute, São Paulo 05503-900, Brazil;
| | - Ana Maria Moro
- Biopharmaceuticals Laboratory, Butantan Institute, São Paulo 05503-900, Brazil;
| | - Denise V. Tambourgi
- Immunochemistry Laboratory, Butantan Institute, São Paulo 05503-900, Brazil; (D.V.T.); (O.A.S.)
| | | |
Collapse
|
9
|
Luz D, Gómez FD, Ferreira RL, Melo BS, Guth BEC, Quintilio W, Moro AM, Presta A, Sacerdoti F, Ibarra C, Chen G, Sidhu SS, Amaral MM, Piazza RMF. The Deleterious Effects of Shiga Toxin Type 2 Are Neutralized In Vitro by FabF8:Stx2 Recombinant Monoclonal Antibody. Toxins (Basel) 2021; 13:toxins13110825. [PMID: 34822608 PMCID: PMC8621789 DOI: 10.3390/toxins13110825] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/14/2021] [Revised: 11/10/2021] [Accepted: 11/15/2021] [Indexed: 12/26/2022] Open
Abstract
Hemolytic Uremic Syndrome (HUS) associated with Shiga-toxigenic Escherichia coli (STEC) infections is the principal cause of acute renal injury in pediatric age groups. Shiga toxin type 2 (Stx2) has in vitro cytotoxic effects on kidney cells, including human glomerular endothelial (HGEC) and Vero cells. Neither a licensed vaccine nor effective therapy for HUS is available for humans. Recombinant antibodies against Stx2, produced in bacteria, appeared as the utmost tool to prevent HUS. Therefore, in this work, a recombinant FabF8:Stx2 was selected from a human Fab antibody library by phage display, characterized, and analyzed for its ability to neutralize the Stx activity from different STEC-Stx2 and Stx1/Stx2 producing strains in a gold standard Vero cell assay, and the Stx2 cytotoxic effects on primary cultures of HGEC. This recombinant Fab showed a dissociation constant of 13.8 nM and a half maximum effective concentration (EC50) of 160 ng/mL to Stx2. Additionally, FabF8:Stx2 neutralized, in different percentages, the cytotoxic effects of Stx2 and Stx1/2 from different STEC strains on Vero cells. Moreover, it significantly prevented the deleterious effects of Stx2 in a dose-dependent manner (up to 83%) in HGEC and protected this cell up to 90% from apoptosis and necrosis. Therefore, this novel and simple anti-Stx2 biomolecule will allow further investigation as a new therapeutic option that could improve STEC and HUS patient outcomes.
Collapse
Affiliation(s)
- Daniela Luz
- Laboratório de Bacteriologia, Instituto Butantan, Sao Paulo 05503-900, Brazil; (D.L.); (R.L.F.); (B.S.M.)
| | - Fernando D. Gómez
- Laboratorio de Fisiopatogenia, Instituto de Fisiología y Biofísica Bernardo Houssay (IFIBIO Houssay-CONICET), Departamento de Fisiología, Facultad de Medicina, Universidad de Buenos Aires, Buenos Aires 1121, Argentina; (F.D.G.); (A.P.); (F.S.); (C.I.)
| | - Raíssa L. Ferreira
- Laboratório de Bacteriologia, Instituto Butantan, Sao Paulo 05503-900, Brazil; (D.L.); (R.L.F.); (B.S.M.)
| | - Bruna S. Melo
- Laboratório de Bacteriologia, Instituto Butantan, Sao Paulo 05503-900, Brazil; (D.L.); (R.L.F.); (B.S.M.)
| | - Beatriz E. C. Guth
- Departamento de Microbiologia, Imunologia e Parasitologia, Universidade Federal de Sāo Paulo, Sao Paulo 04023-062, Brazil;
| | - Wagner Quintilio
- Laboratório de Biofármacos, Instituto Butantan, Sao Paulo 05503-900, Brazil; (W.Q.); (A.M.M.)
| | - Ana Maria Moro
- Laboratório de Biofármacos, Instituto Butantan, Sao Paulo 05503-900, Brazil; (W.Q.); (A.M.M.)
| | - Agostina Presta
- Laboratorio de Fisiopatogenia, Instituto de Fisiología y Biofísica Bernardo Houssay (IFIBIO Houssay-CONICET), Departamento de Fisiología, Facultad de Medicina, Universidad de Buenos Aires, Buenos Aires 1121, Argentina; (F.D.G.); (A.P.); (F.S.); (C.I.)
| | - Flavia Sacerdoti
- Laboratorio de Fisiopatogenia, Instituto de Fisiología y Biofísica Bernardo Houssay (IFIBIO Houssay-CONICET), Departamento de Fisiología, Facultad de Medicina, Universidad de Buenos Aires, Buenos Aires 1121, Argentina; (F.D.G.); (A.P.); (F.S.); (C.I.)
| | - Cristina Ibarra
- Laboratorio de Fisiopatogenia, Instituto de Fisiología y Biofísica Bernardo Houssay (IFIBIO Houssay-CONICET), Departamento de Fisiología, Facultad de Medicina, Universidad de Buenos Aires, Buenos Aires 1121, Argentina; (F.D.G.); (A.P.); (F.S.); (C.I.)
| | - Gang Chen
- Banting and Best Department of Medical Research, Terrence Donnelly Centre for Cellular and Biomolecular Research, University of Toronto, Toronto, OT M5S 3E1, Canada; (G.C.); (S.S.S.)
| | - Sachdev S. Sidhu
- Banting and Best Department of Medical Research, Terrence Donnelly Centre for Cellular and Biomolecular Research, University of Toronto, Toronto, OT M5S 3E1, Canada; (G.C.); (S.S.S.)
| | - María Marta Amaral
- Laboratorio de Fisiopatogenia, Instituto de Fisiología y Biofísica Bernardo Houssay (IFIBIO Houssay-CONICET), Departamento de Fisiología, Facultad de Medicina, Universidad de Buenos Aires, Buenos Aires 1121, Argentina; (F.D.G.); (A.P.); (F.S.); (C.I.)
- Correspondence: (M.M.A.); (R.M.F.P.)
| | - Roxane M. F. Piazza
- Laboratório de Bacteriologia, Instituto Butantan, Sao Paulo 05503-900, Brazil; (D.L.); (R.L.F.); (B.S.M.)
- Correspondence: (M.M.A.); (R.M.F.P.)
| |
Collapse
|
10
|
Smaletz O, Ismael G, Del Pilar Estevez-Diz M, Nascimento ILO, de Morais ALG, Cunha-Junior GF, Azevedo SJ, Alves VA, Moro AM, Yeda FP, Dos Santos ML, Majumder I, Hoffman EW. Phase II consolidation trial with anti-Lewis-Y monoclonal antibody (hu3S193) in platinum-sensitive ovarian cancer after a second remission. Int J Gynecol Cancer 2021; 31:562-568. [PMID: 33664128 DOI: 10.1136/ijgc-2020-002239] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/10/2020] [Revised: 02/18/2021] [Accepted: 02/19/2021] [Indexed: 12/18/2022] Open
Abstract
OBJECTIVE To investigate the efficacy and safety of hu3S193, a humanized anti-Lewis-Y monoclonal antibody, as a consolidation strategy in patients with platinum-sensitive recurrent epithelial ovarian cancer who achieved a second complete response after salvage platinum-doublet chemotherapy. METHODS This single-arm phase II study accrued patients with recurrent epithelial ovarian cancer with Lewis-Y expression by immunohistochemistry who had achieved a second complete response after five to eight cycles of platinum-based chemotherapy. Patients received intravenous infusions of hu3S193, 30 mg/m2 every 2 weeks starting no more than 8 weeks after the last dose of chemotherapy and continuing for 12 doses, until disease progression, or unacceptable toxicity. The primary endpoint was progression-free survival of the second remission. Secondary objectives were safety and pharmacokinetics. RESULTS Twenty-nine patients were enrolled. Most had a papillary/serous histology tumor (94%), stage III disease at diagnosis (75%), and five (17%) underwent secondary cytoreduction before salvage chemotherapy. Two patients were not eligible for efficacy but were considered for toxicity analysis. Eighteen patients (62%) completed the full consolidation treatment while nine patients progressed on treatment. At the time of analysis, 23 patients (85%) of the eligible population had progressed and seven of these patients (26%) had died. Median progression-free survival of the second remission was 12.1 months (95% CI: 10.6-13.9), with a 1-year progression-free survival of the second remission rate of 50.1%. The trial was terminated early since it was unlikely that the primary objective would be achieved. The most commonly reported treatment-related adverse events were nausea (55%) and vomiting (51%). CONCLUSIONS Hu3S193 did not show sufficient clinical activity as consolidation therapy in patients with recurrent epithelial ovarian cancer who achieved a second complete response after platinum-based chemotherapy. TRIAL REGISTRATION NCT01137071.
Collapse
Affiliation(s)
- Oren Smaletz
- Oncology Department, Hospital Israelita Albert Einstein, Sao Paulo, Sao Paulo, Brazil
| | | | - Maria Del Pilar Estevez-Diz
- Instituto do Cancer do Estado de Sao Paulo, Faculdade de Medicina da Universidade de Sao Paulo, Sao Paulo, Sao Paulo, Brazil
| | | | | | | | | | - Venancio A Alves
- Pathology Department, Faculdade de Medicina da Universidade de Sao Paulo, Sao Paulo, Sao Paulo, Brazil
| | | | | | | | | | - Eric W Hoffman
- Ludwig Institute for Cancer Research Ltd, New York, New York, USA
| |
Collapse
|
11
|
Quintilio W, Kapronezai J, Takata DY, Marcelino JR, Moro AM. Tetanus antitoxin potency assessment by surface plasmon resonance and ToBI test. Biologicals 2019; 62:107-110. [PMID: 31519539 DOI: 10.1016/j.biologicals.2019.09.005] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/11/2019] [Revised: 08/16/2019] [Accepted: 09/06/2019] [Indexed: 11/19/2022] Open
Abstract
Potency testing of tetanus antitoxin must be performed in vivo, in a very painful, stressful and prone to high variability assay. It is, therefore, mandatory to find alternatives to this kind of potency assessment. Immunochemical tests as ELISA or ToBI test are already available but usually results in a poor correlation to the in vivo protection. Considering research and development of mono and oligoclonal antibodies against tetanus and the improvement of equine polyclonal antitoxin production and control, we developed an alternative instrumental test for tetanus antitoxin by using surface plasmon resonance. Tetanus antitoxin from hyperimmune equine sera (16 batches) were tested and the results indicated excellent concordance and correlation to the in vivo test (Lin's ρ = 0.9). This innovative approach should now be improved in order to extend it to oligoclonal and monoclonal human antibodies aiming to replace mice for the potency assessment of tetanus antitoxin especially during research and development steps.
Collapse
Affiliation(s)
- Wagner Quintilio
- Laboratory of Biopharmaceuticals in Animal Cells, Instituto Butantan, SP, Brazil.
| | | | - Daniela Yumi Takata
- Laboratory of Biopharmaceuticals in Animal Cells, Instituto Butantan, SP, Brazil
| | | | - Ana Maria Moro
- Laboratory of Biopharmaceuticals in Animal Cells, Instituto Butantan, SP, Brazil
| |
Collapse
|
12
|
Aliprandini E, Takata DY, Lepique A, Kalil J, Boscardin SB, Moro AM. An oligoclonal combination of human monoclonal antibodies able to neutralize tetanus toxin in vivo. Toxicon X 2019; 2:100006. [PMID: 32550563 PMCID: PMC7285915 DOI: 10.1016/j.toxcx.2019.100006] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/26/2018] [Revised: 12/27/2018] [Accepted: 01/10/2019] [Indexed: 12/01/2022] Open
Abstract
The use of antibody-based therapy to treat a variety of diseases and conditions is well documented. The use of antibodies as an antidote to treat tetanus infections was one of the first examples of immunotherapy and remains the standard of care for cases involving potential infections. Plasma-derived immunoglobulins obtained from human or horse pose risks of infection from undetectable emergent viruses or may cause anaphylaxis. Further, there is a lack of consistency between lots. In the search for new formulations, we obtained a series of clonally related human monoclonal antibodies (mAbs) derived from B cells sorted from donors that presented anti-tetanus neutralizing titers. Donors were revaccinated prior to blood collection. Different strategies were used for single-cell sorting, since it was challenging to identify cells at a very low frequency: memory B cell sorting using fluorescent-labeled tetanus toxoid and toxin as baits, and plasmablast sorting done shortly after revaccination. Screening of the recombinant mAbs with the whole tetanus toxin allowed us to select candidates with therapeutic potential, since mAbs to different domains can contribute additively to the neutralizing effect. Because of selective binding to different domains, we tested mAbs individually, or in mixtures of two or three, in the neutralizing in vivo assay specified by Pharmacopeia for the determination of polyclonal hyperimmune sera potency. An oligoclonal mixture of three human mAbs completely neutralized the toxin injected in the animals, signaling an important step for clinical mAb development.
Collapse
Affiliation(s)
- Eduardo Aliprandini
- Laboratory of Biopharmaceuticals in Animal Cells, Instituto Butantan, São Paulo, Brazil.,Interunits Graduate Program in Biotechnology, University of São Paulo, Brazil
| | - Daniela Yumi Takata
- Laboratory of Biopharmaceuticals in Animal Cells, Instituto Butantan, São Paulo, Brazil.,Interunits Graduate Program in Biotechnology, University of São Paulo, Brazil
| | - Ana Lepique
- Dept of Immunology, Biomedical Sciences Institute, University of São Paulo, Brazil
| | - Jorge Kalil
- Laboratory of Immunology, School of Medicine, University of São Paulo, São Paulo, Brazil.,Institute for Investigation in Immunology, iii - INCT (National Institute of Science and Technology), São Paulo, Brazil
| | - Silvia Beatriz Boscardin
- Dept of Parasitology, Biomedical Sciences Institute, University of São Paulo, Brazil.,Institute for Investigation in Immunology, iii - INCT (National Institute of Science and Technology), São Paulo, Brazil
| | - Ana Maria Moro
- Laboratory of Biopharmaceuticals in Animal Cells, Instituto Butantan, São Paulo, Brazil.,Institute for Investigation in Immunology, iii - INCT (National Institute of Science and Technology), São Paulo, Brazil
| |
Collapse
|
13
|
Luz D, Amaral MM, Sacerdoti F, Bernal AM, Quintilio W, Moro AM, Palermo MS, Ibarra C, Piazza RMF. Human Recombinant Fab Fragment Neutralizes Shiga Toxin Type 2 Cytotoxic Effects in vitro and in vivo. Toxins (Basel) 2018; 10:toxins10120508. [PMID: 30513821 PMCID: PMC6315604 DOI: 10.3390/toxins10120508] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/25/2018] [Revised: 11/24/2018] [Accepted: 11/28/2018] [Indexed: 12/13/2022] Open
Abstract
Shiga toxin (Stx) producing Escherichia coli (STEC) is responsible for causing hemolytic uremic syndrome (HUS), a life-threatening thrombotic microangiopathy characterized by thrombocytopenia, hemolytic anemia, and acute renal failure after bacterially induced hemorrhagic diarrhea. Until now, there has been neither an effective treatment nor method of prevention for the deleterious effects caused by Stx intoxication. Antibodies are well recognized as affinity components of therapeutic drugs; thus, a previously obtained recombinant human FabC11:Stx2 fragment was used to neutralize Stx2 in vitro in a Vero cell viability assay. Herein, we demonstrated that this fragment neutralized, in a dose-dependent manner, the cytotoxic effects of Stx2 on human glomerular endothelial cells, on human proximal tubular epithelial cells, and prevented the morphological alterations induced by Stx2. FabC11:Stx2 protected mice from a lethal dose of Stx2 by toxin-antibody pre-incubation. Altogether, our results show the ability of a new encouraging molecule to prevent Stx-intoxication symptoms during STEC infection.
Collapse
Affiliation(s)
- Daniela Luz
- Laboratório de Bacteriologia, Instituto Butantan, São Paulo 05503900, Brasil.
| | - Maria Marta Amaral
- Laboratorio de Fisiopatogenia, Departamento de Fisiología, Instituto de Fisiología y Biofísica Bernardo Houssay (IFIBIO Houssay-CONICET), Facultad de Medicina, Universidad de Buenos Aires, Buenos Aires C1121, Argentina.
| | - Flavia Sacerdoti
- Laboratorio de Fisiopatogenia, Departamento de Fisiología, Instituto de Fisiología y Biofísica Bernardo Houssay (IFIBIO Houssay-CONICET), Facultad de Medicina, Universidad de Buenos Aires, Buenos Aires C1121, Argentina.
| | - Alan Mauro Bernal
- Laboratorio de Patogénesis e Inmunología de Procesos Infecciosos, Instituto de Medicina Experimental, (IMEX)-CONICET-Academia Nacional de Medicina, Buenos Aires C1425, Argentina.
| | - Wagner Quintilio
- Laboratório de Biofármacos em Células Animais, Instituto Butantan, São Paulo, SP 05503-900, Brazil.
| | - Ana Maria Moro
- Laboratório de Biofármacos em Células Animais, Instituto Butantan, São Paulo, SP 05503-900, Brazil.
| | - Marina Sandra Palermo
- Laboratorio de Patogénesis e Inmunología de Procesos Infecciosos, Instituto de Medicina Experimental, (IMEX)-CONICET-Academia Nacional de Medicina, Buenos Aires C1425, Argentina.
| | - Cristina Ibarra
- Laboratorio de Fisiopatogenia, Departamento de Fisiología, Instituto de Fisiología y Biofísica Bernardo Houssay (IFIBIO Houssay-CONICET), Facultad de Medicina, Universidad de Buenos Aires, Buenos Aires C1121, Argentina.
| | | |
Collapse
|
14
|
Affiliation(s)
| | | | | | | | - Ana Maria Moro
- Butantan Institute, Brazil; National Institute for Science and Technology, Brazil
| |
Collapse
|
15
|
de Oliveira ÉA, Faintuch BL, Seo D, Barbezan AB, Funari A, Targino RC, Moro AM. Radiolabeled GX1 Peptide for Tumor Angiogenesis Imaging. Appl Biochem Biotechnol 2018; 185:863-874. [DOI: 10.1007/s12010-018-2700-z] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/23/2017] [Accepted: 01/15/2018] [Indexed: 02/06/2023]
|
16
|
Pesudo V, Borge MJG, Moro AM, Lay JA, Nácher E, Gómez-Camacho J, Tengblad O, Acosta L, Alcorta M, Alvarez MAG, Andreoiu C, Bender PC, Braid R, Cubero M, Di Pietro A, Fernández-García JP, Figuera P, Fisichella M, Fulton BR, Garnsworthy AB, Hackman G, Hager U, Kirsebom OS, Kuhn K, Lattuada M, Marquínez-Durán G, Martel I, Miller D, Moukaddam M, O'Malley PD, Perea A, Rajabali MM, Sánchez-Benítez AM, Sarazin F, Scuderi V, Svensson CE, Unsworth C, Wang ZM. Scattering of the Halo Nucleus ^{11}Be on ^{197}Au at Energies around the Coulomb Barrier. Phys Rev Lett 2017; 118:152502. [PMID: 28452556 DOI: 10.1103/physrevlett.118.152502] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 06/15/2016] [Indexed: 06/07/2023]
Abstract
Angular distributions of the elastic, inelastic, and breakup cross sections of the halo nucleus ^{11}Be on ^{197}Au were measured at energies below (E_{lab}=31.9 MeV) and around (39.6 MeV) the Coulomb barrier. These three channels were unambiguously separated for the first time for reactions of ^{11}Be on a high-Z target at low energies. The experiment was performed at TRIUMF (Vancouver, Canada). The differential cross sections were compared with three different calculations: semiclassical, inert-core continuum-coupled-channels and continuum-coupled-channels ones with including core deformation. These results show conclusively that the elastic and inelastic differential cross sections can only be accounted for if core-excited admixtures are taken into account. The cross sections for these channels strongly depend on the B(E1) distribution in ^{11}Be, and the reaction mechanism is sensitive to the entanglement of core and halo degrees of freedom in ^{11}Be.
Collapse
Affiliation(s)
- V Pesudo
- Instituto de Estructura de la Materia, CSIC, 28006 Madrid, Spain
- Department of Physics, University of the Western Cape, P/B X17, Bellville ZA-7535, South Africa
- iThemba LABS, Somerset West 7129, South Africa
| | - M J G Borge
- Instituto de Estructura de la Materia, CSIC, 28006 Madrid, Spain
- ISOLDE-EP, CERN, CH-1211 Geneva 23, Switzerland
| | - A M Moro
- Departamento de FAMN, Universidad de Sevilla, 41080 Sevilla, Spain
| | - J A Lay
- Dipartimento di Fisica e Astr. "Galileo Galilei", Univ. di Padova, 35131 Padova, Italy
- INFN, Sezione di Padova, via Marzolo, 8, 35131 Padova, Italy
| | - E Nácher
- Instituto de Estructura de la Materia, CSIC, 28006 Madrid, Spain
| | - J Gómez-Camacho
- Departamento de FAMN, Universidad de Sevilla, 41080 Sevilla, Spain
- CN de Aceleradores (U. Sevilla, J. Andalucía, CSIC), 41092 Sevilla, Spain
| | - O Tengblad
- Instituto de Estructura de la Materia, CSIC, 28006 Madrid, Spain
| | - L Acosta
- Instituto de Física, Universidad Nacional Autónoma de México, A.P. 20-364, Cd.Mx. 01000 Mexico
| | - M Alcorta
- Physics Division, Argonne National Laboratory, Argonne, Illinois 60439, USA
| | - M A G Alvarez
- Instituto de Física, Universidade de São Paulo, 05508-090 São Paulo, Brazil
| | - C Andreoiu
- Department of Chemistry, Simon Fraser University, Burnaby, British Columbia, Canada V5A 1S6
| | - P C Bender
- TRIUMF, 4004 Wesbrook Mall, Vancouver, British Columbia V6T 2A3, Canada
| | - R Braid
- Physics Department, Colorado School of Mines, Golden, Colorado 80401, USA
| | - M Cubero
- Instituto de Estructura de la Materia, CSIC, 28006 Madrid, Spain
- CICANUM, Universidad de Costa Rica, Apdo. 2060 San José, Costa Rica
| | - A Di Pietro
- Laboratori Nazionali del Sud, INFN, via Santa Sofia 62, 95123 Catania, Italy
| | - J P Fernández-García
- Departamento de FAMN, Universidad de Sevilla, 41080 Sevilla, Spain
- Laboratori Nazionali del Sud, INFN, via Santa Sofia 62, 95123 Catania, Italy
- CN de Aceleradores (U. Sevilla, J. Andalucía, CSIC), 41092 Sevilla, Spain
| | - P Figuera
- Laboratori Nazionali del Sud, INFN, via Santa Sofia 62, 95123 Catania, Italy
| | - M Fisichella
- Laboratori Nazionali del Sud, INFN, via Santa Sofia 62, 95123 Catania, Italy
| | - B R Fulton
- Department of Physics, University of York, YO 10 5DD Heslington, York, United Kingdom
| | - A B Garnsworthy
- TRIUMF, 4004 Wesbrook Mall, Vancouver, British Columbia V6T 2A3, Canada
| | - G Hackman
- TRIUMF, 4004 Wesbrook Mall, Vancouver, British Columbia V6T 2A3, Canada
| | - U Hager
- National Superconducting Cyclotron Laboratory, Michigan State University, East Lansing, Michigan 48824, USA
| | - O S Kirsebom
- TRIUMF, 4004 Wesbrook Mall, Vancouver, British Columbia V6T 2A3, Canada
- Department of Physics and Astronomy, Aarhus University, 8000 Aarhus, Denmark
| | - K Kuhn
- Physics Department, Colorado School of Mines, Golden, Colorado 80401, USA
| | - M Lattuada
- Laboratori Nazionali del Sud, INFN, via Santa Sofia 62, 95123 Catania, Italy
- Dipartimento di Fisica e Astronomia, via Santa Sofia 64, 95123 Catania, Italy
| | - G Marquínez-Durán
- Departamento de Ciencias integradas, Universidad de Huelva, 21071 Huelva, Spain
| | - I Martel
- Departamento de Ciencias integradas, Universidad de Huelva, 21071 Huelva, Spain
| | - D Miller
- TRIUMF, 4004 Wesbrook Mall, Vancouver, British Columbia V6T 2A3, Canada
| | - M Moukaddam
- TRIUMF, 4004 Wesbrook Mall, Vancouver, British Columbia V6T 2A3, Canada
| | - P D O'Malley
- Physics Department, Colorado School of Mines, Golden, Colorado 80401, USA
| | - A Perea
- Instituto de Estructura de la Materia, CSIC, 28006 Madrid, Spain
| | - M M Rajabali
- TRIUMF, 4004 Wesbrook Mall, Vancouver, British Columbia V6T 2A3, Canada
| | - A M Sánchez-Benítez
- Departamento de Ciencias integradas, Universidad de Huelva, 21071 Huelva, Spain
| | - F Sarazin
- Physics Department, Colorado School of Mines, Golden, Colorado 80401, USA
| | - V Scuderi
- Laboratori Nazionali del Sud, INFN, via Santa Sofia 62, 95123 Catania, Italy
| | - C E Svensson
- Department of Physics. University of Guelph, Guelph, Ontario N1G 2W1, Canada
| | - C Unsworth
- TRIUMF, 4004 Wesbrook Mall, Vancouver, British Columbia V6T 2A3, Canada
| | - Z M Wang
- TRIUMF, 4004 Wesbrook Mall, Vancouver, British Columbia V6T 2A3, Canada
- Department of Chemistry, Simon Fraser University, Burnaby, British Columbia, Canada V5A 1S6
| |
Collapse
|
17
|
Faintuch BL, Seo D, de Oliveira EA, Targino RC, Moro AM. Evaluation of the Influence of the Conjugation Site of the Chelator Agent HYNIC to GLP1 Antagonist Radiotracer for Insulinoma Diagnosis. Curr Radiopharm 2017; 10:65-72. [PMID: 28164753 DOI: 10.2174/1874471010666170126143636] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/24/2016] [Revised: 01/12/2017] [Accepted: 01/18/2017] [Indexed: 11/22/2022]
Abstract
BACKGROUND AND OBJECTIVE Radiotracer diagnosis of insulinoma, can be done using somatostatin or glucagon-like peptide 1 (GLP-1). Performance of GLP-1 antagonists tends to be better than of agonists. METHODS We investigated the uptake of the antagonist exendin (9-39), radiolabeled with technetium- 99m. Two different sites of the biomolecule were selected for chelator attachment. RESULTS HYNIC-βAla chelator attached to serine (C- terminus) of exendin, was associated with higher tumor uptake than to aspartate (N- terminus). CONCLUSION The chelator position in the biomolecule influenced receptor uptake.
Collapse
Affiliation(s)
- Bluma Linkowski Faintuch
- Institute of Energy and Nuclear Research Radiopharmacy Center Av. Prof. Lineu Prestes, 2242 São Paulo, Brazil
| | - Daniele Seo
- Radiopharmacy Center, Institute of Energy and Nuclear Research, São Paulo, Brazil
| | | | | | - Ana Maria Moro
- Laboratory of Biopharmacology in Animal Cells, Butantan Institute, Sao Paulo, Brazil
| |
Collapse
|
18
|
Tsuruta LR, Lopes dos Santos M, Yeda FP, Okamoto OK, Moro AM. Genetic analyses of Per.C6 cell clones producing a therapeutic monoclonal antibody regarding productivity and long-term stability. Appl Microbiol Biotechnol 2016; 100:10031-10041. [DOI: 10.1007/s00253-016-7841-9] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/29/2016] [Revised: 08/21/2016] [Accepted: 09/07/2016] [Indexed: 11/27/2022]
|
19
|
de Aguiar RB, Parise CB, Souza CRT, Braggion C, Quintilio W, Moro AM, Navarro Marques FL, Buchpiguel CA, Chammas R, de Moraes JZ. Blocking FGF2 with a new specific monoclonal antibody impairs angiogenesis and experimental metastatic melanoma, suggesting a potential role in adjuvant settings. Cancer Lett 2015; 371:151-60. [PMID: 26655277 DOI: 10.1016/j.canlet.2015.11.030] [Citation(s) in RCA: 24] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/22/2015] [Revised: 11/26/2015] [Accepted: 11/27/2015] [Indexed: 01/06/2023]
Abstract
Compelling evidence suggests that fibroblast growth factor 2 (FGF2), overexpressed in melanomas, plays an important role in tumor growth, angiogenesis and metastasis. In this study, we evaluated the therapeutic use of a new anti-FGF2 monoclonal antibody (mAb), 3F12E7, using for that the B16-F10 melanoma model. The FGF2 neutralizing effect of this antibody was certified by in vitro assays, which allowed the further track of its possible in vivo application. 3F12E7 mAb could be retained in B16-F10 tumors, as shown by antibody low-pH elution and nuclear medicine studies, and also led to reduction in number and size of metastatic foci in lungs, when treatment starts one day after intravenous injection of B16-F10 cells. Such data were accompanied by decreased CD34(+) tumor vascular density and impaired subcutaneous tumor outgrowth. Treatments starting one week after melanoma cell intravenous injection did not reduce tumor burden, remaining the therapeutic effectiveness restricted to early-adopted regimens. Altogether, the presented anti-FGF2 3F12E7 mAb stands as a promising agent to treat metastatic melanoma tumors in adjuvant settings.
Collapse
Affiliation(s)
- Rodrigo Barbosa de Aguiar
- Departamento de Radiologia e Oncologia, Faculdade de Medicina, Universidade de São Paulo, Avenida Dr Arnaldo 251, 01246-000 São Paulo, SP, Brazil; Departamento de Biofísica, Escola Paulista de Medicina, Universidade Federal de São Paulo, Rua Botucatu 862, 04023-062 São Paulo, SP, Brazil
| | - Carolina Bellini Parise
- Departamento de Biofísica, Escola Paulista de Medicina, Universidade Federal de São Paulo, Rua Botucatu 862, 04023-062 São Paulo, SP, Brazil
| | - Carolina Rosal Teixeira Souza
- Departamento de Radiologia e Oncologia, Faculdade de Medicina, Universidade de São Paulo, Avenida Dr Arnaldo 251, 01246-000 São Paulo, SP, Brazil
| | - Camila Braggion
- Departamento de Biofísica, Escola Paulista de Medicina, Universidade Federal de São Paulo, Rua Botucatu 862, 04023-062 São Paulo, SP, Brazil
| | - Wagner Quintilio
- Laboratório de Biofármacos em Células Animais, Instituto Butantan, Avenida Vital Brasil 1500, 05503-900 São Paulo, SP, Brazil
| | - Ana Maria Moro
- Laboratório de Biofármacos em Células Animais, Instituto Butantan, Avenida Vital Brasil 1500, 05503-900 São Paulo, SP, Brazil
| | - Fabio Luiz Navarro Marques
- Centro de Medicina Nuclear, Faculdade de Medicina, Universidade de São Paulo, Trav. Rua Dr. Ovídio Pires de Campos s/n, 05403-010 São Paulo, SP, Brazil
| | - Carlos Alberto Buchpiguel
- Centro de Medicina Nuclear, Faculdade de Medicina, Universidade de São Paulo, Trav. Rua Dr. Ovídio Pires de Campos s/n, 05403-010 São Paulo, SP, Brazil
| | - Roger Chammas
- Departamento de Radiologia e Oncologia, Faculdade de Medicina, Universidade de São Paulo, Avenida Dr Arnaldo 251, 01246-000 São Paulo, SP, Brazil.
| | - Jane Zveiter de Moraes
- Departamento de Biofísica, Escola Paulista de Medicina, Universidade Federal de São Paulo, Rua Botucatu 862, 04023-062 São Paulo, SP, Brazil.
| |
Collapse
|
20
|
de Oliveira ÉA, Faintuch BL, Targino RC, Moro AM, Martinez RCR, Pagano RL, Fonoff ET, Carneiro CDG, Garcez AT, Faria DDP, Buchpiguel CA. Evaluation of GX1 and RGD-GX1 peptides as new radiotracers for angiogenesis evaluation in experimental glioma models. Amino Acids 2015; 48:821-831. [PMID: 26592499 DOI: 10.1007/s00726-015-2130-y] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/22/2015] [Accepted: 11/04/2015] [Indexed: 01/31/2023]
Abstract
Gliomas are the most common type among all central nervous system tumors. The aggressiveness of gliomas is correlated with the level of angiogenesis and is often associated with prognosis. The aim of this study is to evaluate the novel GX1 peptide and the heterodimer RGD-GX1 radiolabeled with technetium-99m, for angiogenesis detection in glioma models. Radiolabeling and radiochemical controls were assessed for both radioconjugates. In vitro binding studies in glioma tumor cells were performed, as well as biodistribution in SCID mice bearing tumor cells, in order to evaluate the biological behavior and tumor uptake of the radiocomplexes. Blocking and imaging studies were also conducted. MicroSPECT/CT images were acquired in animals with experimentally implanted intracranial tumor. Open field activity was performed to evaluate behavior, as well as perfusion and histology analysis. The radiochemical purity of both radiotracers was greater than 96 %. In vitro binding studies revealed rather similar binding profi le for each molecule. The highest binding was for RGD-GX1 peptide at 120 min in U87MG cells (1.14 ± 0.35 %). Tumor uptake was also favorable for RGD-GX1 peptide in U87MG cells, reaching 2.96 ± 0.70 % at 1 h p.i. with 47 % of blocking. Imaging studies also indicated better visualization for RGD-GX1 peptide in U87MG cells. Behavior evaluation pointed brain damage and histology studies confirmed actual tumor in the uptake site. The results with the angiogenesis seeking molecule (99m)Tc-HYNIC-E-[c(RGDfk)-c(GX1)] were successful, and better than with (99m)Tc-HYNIC-PEG4-c(GX1). Future studies targeting angiogenesis in other glioma and nonglioma tumor models are recommended.
Collapse
Affiliation(s)
- Érica Aparecida de Oliveira
- Radiopharmacy Center, Institute of Energy and Nuclear Research, Av. Prof. Lineu Prestes, 2242, São Paulo, 05508-000, Brazil. .,School of Pharmaceutical Sciences, University of Sao Paulo, Av. Prof. Lineu Prestes, 580 Bloco 17, São Paulo, 05508-900, Brazil.
| | - Bluma Linkowski Faintuch
- Radiopharmacy Center, Institute of Energy and Nuclear Research, Av. Prof. Lineu Prestes, 2242, São Paulo, 05508-000, Brazil
| | - Roselaine Campos Targino
- Laboratory of Biopharmacology in Animal Cells, Butantan Institute, Av. Vital Brasil, 1500, Sao Paulo, 05503-900, Brazil
| | - Ana Maria Moro
- Laboratory of Biopharmacology in Animal Cells, Butantan Institute, Av. Vital Brasil, 1500, Sao Paulo, 05503-900, Brazil
| | - Raquel Chacon Ruiz Martinez
- Laboratory of Neuromodulation and Experimental Pain, Teaching and Research Institute, Hospital Sírio-Libanês, Rua Professor Daher Cutait, 69, Sao Paulo, 01308-060, Brazil
| | - Rosana Lima Pagano
- Laboratory of Neuromodulation and Experimental Pain, Teaching and Research Institute, Hospital Sírio-Libanês, Rua Professor Daher Cutait, 69, Sao Paulo, 01308-060, Brazil
| | - Erich Talamoni Fonoff
- Laboratory of Neuromodulation and Experimental Pain, Teaching and Research Institute, Hospital Sírio-Libanês, Rua Professor Daher Cutait, 69, Sao Paulo, 01308-060, Brazil.,Division of Functional Neurosurgery, Institute of Psychiatry of Hospital das Clinicas and Department of Neurology, School of Medicine, University of São Paulo, R. Dr. Ovídio Pires de Campos, 785, São Paulo, 01060-970, Brazil
| | - Camila de Godoi Carneiro
- Nuclear Medicine Laboratory (LIM 43), Medical School, University of São Paulo, Av. Dr. Enéas de Carvalho Aguiar, s/nº-Rua 1, Sao Paulo, 05403-900, Brazil
| | - Alexandre Teles Garcez
- Nuclear Medicine Laboratory (LIM 43), Medical School, University of São Paulo, Av. Dr. Enéas de Carvalho Aguiar, s/nº-Rua 1, Sao Paulo, 05403-900, Brazil
| | - Daniele de Paula Faria
- Nuclear Medicine Laboratory (LIM 43), Medical School, University of São Paulo, Av. Dr. Enéas de Carvalho Aguiar, s/nº-Rua 1, Sao Paulo, 05403-900, Brazil
| | - Carlos Alberto Buchpiguel
- Nuclear Medicine Laboratory (LIM 43), Medical School, University of São Paulo, Av. Dr. Enéas de Carvalho Aguiar, s/nº-Rua 1, Sao Paulo, 05403-900, Brazil
| |
Collapse
|
21
|
Lindegren S, Andrade LNS, Bäck T, Machado CML, Horta BB, Buchpiguel C, Moro AM, Okamoto OK, Jacobsson L, Cederkrantz E, Washiyama K, Aneheim E, Palm S, Jensen H, Tuma MCB, Chammas R, Hultborn R, Albertsson P. Binding Affinity, Specificity and Comparative Biodistribution of the Parental Murine Monoclonal Antibody MX35 (Anti-NaPi2b) and Its Humanized Version Rebmab200. PLoS One 2015; 10:e0126298. [PMID: 25970341 PMCID: PMC4430291 DOI: 10.1371/journal.pone.0126298] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/19/2014] [Accepted: 03/31/2015] [Indexed: 12/17/2022] Open
Abstract
The aim of this preclinical study was to evaluate the characteristics of the monoclonal antibody Rebmab200, which is a humanized version of the ovarian-specific murine antibody MX35. This investigation contributes to the foundation for future clinical α-radioimmunotherapy of minimal residual ovarian cancer with 211At-Rebmab200. Here, the biodistribution of 211At-Rebmab200 was evaluated, as was the utility of 99mTc-Rebmab200 for bioimaging. Rebmab200 was directly compared with its murine counterpart MX35 in terms of its in-vitro capacity for binding the immobilized NaPi2B epitope and live cells; we also assessed its biodistribution in nude mice carrying subcutaneous OVCAR-3 tumors. Tumor antigen and cell binding were similar between Rebmab200 and murine MX35, as was biodistribution, including normal tissue uptake and in-vivo tumor binding. We also demonstrated that 99mTc-Rebmab200 can be used for single-photon emission computed tomography of subcutaneous ovarian carcinomas in tumor-bearing mice. Taken together, our data support the further development of Rebmab200 for radioimmunotherapy and diagnostics.
Collapse
MESH Headings
- Animals
- Antibodies, Monoclonal/pharmacokinetics
- Antibodies, Monoclonal/pharmacology
- Antibodies, Monoclonal, Humanized/pharmacokinetics
- Antibodies, Monoclonal, Humanized/pharmacology
- Antibody Affinity
- Antibody Specificity
- Antigens, Neoplasm/genetics
- Antigens, Neoplasm/metabolism
- Antineoplastic Agents/pharmacokinetics
- Antineoplastic Agents/pharmacology
- Astatine/chemistry
- Carcinoma/diagnostic imaging
- Carcinoma/genetics
- Carcinoma/immunology
- Carcinoma/therapy
- Cell Line, Tumor
- Female
- Gene Expression
- Humans
- Mice
- Mice, Nude
- Ovarian Neoplasms/diagnostic imaging
- Ovarian Neoplasms/genetics
- Ovarian Neoplasms/immunology
- Ovarian Neoplasms/therapy
- Radioimmunotherapy
- Radiopharmaceuticals/chemistry
- Sodium-Phosphate Cotransporter Proteins, Type IIb/genetics
- Sodium-Phosphate Cotransporter Proteins, Type IIb/metabolism
- Technetium/chemistry
- Tissue Distribution
- Tomography, Emission-Computed, Single-Photon
- Xenograft Model Antitumor Assays
Collapse
Affiliation(s)
- Sture Lindegren
- Department of Radiation Physics, Sahlgrenska Academy, University of Gothenburg,Gothenburg, Sweden
| | - Luciana N. S. Andrade
- Recepta Biopharma, São Paulo, Brasil
- Centro de Investigação Translacional em Oncologia (LIM24), Instituto do Câncer do Estado de São Paulo, Departamento de Radiologia e Oncologia, Faculdade de Medicina, Universidade de São Paulo, São Paulo, Brasil
| | - Tom Bäck
- Department of Radiation Physics, Sahlgrenska Academy, University of Gothenburg,Gothenburg, Sweden
| | - Camila Maria L. Machado
- Centro de Investigação Translacional em Oncologia (LIM24), Instituto do Câncer do Estado de São Paulo, Departamento de Radiologia e Oncologia, Faculdade de Medicina, Universidade de São Paulo, São Paulo, Brasil
- Laboratório de Investigação Médica Radioisótopos-LIM43, Departamento de Radiologiae Oncologia, Faculdade de Medicina, Universidade de São Paulo, São Paulo, Brasil
| | | | - Carlos Buchpiguel
- Laboratório de Investigação Médica Radioisótopos-LIM43, Departamento de Radiologiae Oncologia, Faculdade de Medicina, Universidade de São Paulo, São Paulo, Brasil
| | - Ana Maria Moro
- Laboratório de Biofármacos em Células Animais, Instituto Butantan, São Paulo, Brasil
| | - Oswaldo Keith Okamoto
- Recepta Biopharma, São Paulo, Brasil
- Departamento de Genética e Biologia Evolutiva, Instituto de Biociências, Universidade de São Paulo, São Paulo, Brasil
| | - Lars Jacobsson
- Department of Radiation Physics, Sahlgrenska Academy, University of Gothenburg,Gothenburg, Sweden
| | - Elin Cederkrantz
- Department of Radiation Physics, Sahlgrenska Academy, University of Gothenburg,Gothenburg, Sweden
| | - Kohshin Washiyama
- Department of Radiation Physics, Sahlgrenska Academy, University of Gothenburg,Gothenburg, Sweden
| | - Emma Aneheim
- Department of Radiation Physics, Sahlgrenska Academy, University of Gothenburg,Gothenburg, Sweden
| | - Stig Palm
- Department of Radiation Physics, Sahlgrenska Academy, University of Gothenburg,Gothenburg, Sweden
| | - Holger Jensen
- Cyclotron and PET Unit, KF-3982, Rigshospitalet, Copenhagen, Denmark
| | | | - Roger Chammas
- Centro de Investigação Translacional em Oncologia (LIM24), Instituto do Câncer do Estado de São Paulo, Departamento de Radiologia e Oncologia, Faculdade de Medicina, Universidade de São Paulo, São Paulo, Brasil
| | - Ragnar Hultborn
- Department of Oncology, Sahlgrenska Academy, University of Gothenburg, Gothenburg Sweden
| | - Per Albertsson
- Department of Oncology, Sahlgrenska Academy, University of Gothenburg, Gothenburg Sweden
| |
Collapse
|
22
|
Abstract
Many patents for the first biologicals derived from recombinant technology and, more recently, monoclonal antibodies (mAbs) are expiring. Naturally, biosimilars are becoming an increasingly important area of interest for the pharmaceutical industry worldwide, not only for emergent countries that need to import biologic products. This review shows the evolution of biosimilar development regarding regulatory, manufacturing bioprocess, comparability, and marketing. The regulatory landscape is evolving globally, whereas analytical structure and functional analyses provide the foundation of a biosimilar development program. The challenges to develop and demonstrate biosimilarity should overcome the inherent differences in the bioprocess manufacturing and physicochemical and biological characterization of a biosimilar compared to several lots of the reference product. The implementation of approaches, such as Quality by Design (QbD), will provide products with defined specifications in relation to quality, purity, safety, and efficacy that were not possible when the reference product was developed. Actually, the need to prove comparability to the reference product by the biosimilar industry has increased the knowledge about the product and the production-process associated by the use of powerful analytical tools. The technological challenges to make copies of biologic products while attending regulatory and market demands are expected to help innovation in the direction of attaining more productive manufacturing processes.
Collapse
Affiliation(s)
- Lilian Rumi Tsuruta
- Lab. Biofármacos em Células Animais do Instituto Butantan, São Paulo, SP, 05503-900, Brazil
| | | | - Ana Maria Moro
- Lab. Biofármacos em Células Animais do Instituto Butantan, São Paulo, SP, 05503-900, Brazil.,iii/INCT-Instituto de Investigação em Imunologia, USP, São Paulo, SP, Brazil
| |
Collapse
|
23
|
Novo JB, Targino Valota RC, Moro AM, Raw I, Ho PL. Adaptation of glucocerebrosidase-producing CHO cells to serum-free suspension culture. BMC Proc 2014. [PMCID: PMC4204098 DOI: 10.1186/1753-6561-8-s4-p46] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022] Open
|
24
|
Faintuch BL, Oliveira EA, Targino RC, Moro AM. Radiolabeled NGR phage display peptide sequence for tumor targeting. Appl Radiat Isot 2014; 86:41-5. [PMID: 24480451 DOI: 10.1016/j.apradiso.2013.12.035] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/28/2013] [Revised: 12/17/2013] [Accepted: 12/27/2013] [Indexed: 01/16/2023]
Abstract
The asparagine-glycine-arginine (NGR) peptide sequence found by phage display, was radiolabeled with technetium-99m and tested in different tumor models. Similar uptake occurred with ovarian and lung tumor cells. Biodistribution of the radiotracer revealed predominant renal excretion with more substantial uptake in animals bearing ovarian tumor cells. In contrast imaging studies indicated better visualization for lung tumor. NGR peptide was characterized as a promising diagnostic candidate, particularly for lung cancer. Improvements are envisaged using NGR combined with RGD as a heterodimer molecule.
Collapse
Affiliation(s)
- B L Faintuch
- Radiopharmacy, Institute of Energy and Nuclear Research, Av. Prof. Lineu Prestes 2242, 05508-000 São Paulo, SP, Brazil.
| | - E A Oliveira
- Radiopharmacy, Institute of Energy and Nuclear Research, Av. Prof. Lineu Prestes 2242, 05508-000 São Paulo, SP, Brazil
| | - R C Targino
- Laboratory of Biopharmacology in Animal Cells, Butantan Institute, Av. Vital Brazil 1500, 05503900 São Paulo, SP, Brazil
| | - A M Moro
- Laboratory of Biopharmacology in Animal Cells, Butantan Institute, Av. Vital Brazil 1500, 05503900 São Paulo, SP, Brazil
| |
Collapse
|
25
|
Van Weyenbergh J, Decanine D, Schnitman SV, Moro AM, Kalil J, Kruschewsky RA, Galvão-Castro B. Anti-CD3 monoclonal antibody as a possible therapeutic alternative in HAM/TSP. Retrovirology 2014. [PMCID: PMC4044874 DOI: 10.1186/1742-4690-11-s1-o40] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/18/2022] Open
|
26
|
Santos KS, Stephano MA, Marcelino JR, Ferreira VMR, Rocha T, Caricati C, Higashi HG, Moro AM, Kalil JE, Malaspina O, Castro FFM, Palma MS. Production of the first effective hyperimmune equine serum antivenom against Africanized bees. PLoS One 2013; 8:e79971. [PMID: 24236166 PMCID: PMC3827448 DOI: 10.1371/journal.pone.0079971] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/11/2013] [Accepted: 10/07/2013] [Indexed: 11/22/2022] Open
Abstract
Victims of massive bee attacks become extremely ill, presenting symptoms ranging from dizziness and headache to acute renal failure and multiple organ failure that can lead to death. Previous attempts to develop specific antivenom to treat these victims have been unsuccessful. We herein report a F(ab)(´)(2)-based antivenom raised in horse as a potential new treatment for victims of multiple bee stings. The final product contains high specific IgG titers and is effective in neutralizing toxic effects, such as hemolysis, cytotoxicity and myotoxicity. The assessment of neutralization was revised and hemolysis, the primary toxic effect of these stings, was fully neutralized in vivo for the first time.
Collapse
Affiliation(s)
- Keity Souza Santos
- Division of Clinical Immunology and Allergy, University of São Paulo School of Medicine, FMUSP, São Paulo, Brazil
- Institute for Investigation in Immunology–INCT, São Paulo, SP, Brazil
- Heart Institute (InCor), LIM-19, University of São Paulo School of Medicine, São Paulo, SP, Brazil
| | | | | | - Virginia Maria Resende Ferreira
- Division of Clinical Immunology and Allergy, University of São Paulo School of Medicine, FMUSP, São Paulo, Brazil
- Institute for Investigation in Immunology–INCT, São Paulo, SP, Brazil
| | - Thalita Rocha
- Medical School, São Francisco University, Bragança Paulista, SP, Brazil
| | - Celso Caricati
- Special Pilot Laboratory of Research and Development of Veterinary Immunobiologicals, Butantan Institute, São Paulo, SP, Brazil
| | | | - Ana Maria Moro
- Institute for Investigation in Immunology–INCT, São Paulo, SP, Brazil
- Laboratory of Biopharmaceuticals in Animal Cells, Butantan Institute, São Paulo, SP, Brazil
| | - Jorge Elias Kalil
- Division of Clinical Immunology and Allergy, University of São Paulo School of Medicine, FMUSP, São Paulo, Brazil
- Institute for Investigation in Immunology–INCT, São Paulo, SP, Brazil
- Heart Institute (InCor), LIM-19, University of São Paulo School of Medicine, São Paulo, SP, Brazil
| | - Osmar Malaspina
- Institute for Investigation in Immunology–INCT, São Paulo, SP, Brazil
- Department of Biology/Institute of Biosciences, Center for the Study of Social Insects, University of São Paulo State (UNESP), Rio Claro, SP, Brazil
| | - Fabio Fernandes Morato Castro
- Division of Clinical Immunology and Allergy, University of São Paulo School of Medicine, FMUSP, São Paulo, Brazil
- Institute for Investigation in Immunology–INCT, São Paulo, SP, Brazil
- Heart Institute (InCor), LIM-19, University of São Paulo School of Medicine, São Paulo, SP, Brazil
| | - Mário Sérgio Palma
- Institute for Investigation in Immunology–INCT, São Paulo, SP, Brazil
- Department of Biology/Institute of Biosciences, Center for the Study of Social Insects, University of São Paulo State (UNESP), Rio Claro, SP, Brazil
| |
Collapse
|
27
|
dos Santos ML, Yeda FP, Tsuruta LR, Horta BB, Pimenta AA, Degaki TL, Soares IC, Tuma MC, Okamoto OK, Alves VAF, Old LJ, Ritter G, Moro AM. Rebmab200, a humanized monoclonal antibody targeting the sodium phosphate transporter NaPi2b displays strong immune mediated cytotoxicity against cancer: a novel reagent for targeted antibody therapy of cancer. PLoS One 2013; 8:e70332. [PMID: 23936189 PMCID: PMC3729455 DOI: 10.1371/journal.pone.0070332] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/29/2013] [Accepted: 06/21/2013] [Indexed: 11/19/2022] Open
Abstract
NaPi2b, a sodium-dependent phosphate transporter, is highly expressed in ovarian carcinomas and is recognized by the murine monoclonal antibody MX35. The antibody had shown excellent targeting to ovarian cancer in several early phase clinical trials but being murine the antibody's full therapeutic potential could not be explored. To overcome this impediment we developed a humanized antibody version named Rebmab200, expressed in human PER.C6® cells and cloned by limiting dilution. In order to select a clone with high therapeutic potential clones were characterized using a series of physicochemical assays, flow cytometry, real-time surface plasmon resonance, glycosylation analyses, immunohistochemistry, antibody-dependent cell-mediated cytotoxicity, complement-dependent-cytotoxicity assays and quantitative PCR. Comparative analyses of Rebmab200 and MX35 monoclonal antibodies demonstrated that the two antibodies had similar specificity for NaPi2b by flow cytometry with a panel of 30 cell lines and maintained similar kinetic parameters. Robust and high producer cell clones potentially suitable for use in manufacturing were obtained. Rebmab200 antibodies were assessed by immunohistochemistry using a large panel of tissues including human carcinomas of ovarian, lung, kidney and breast origin. An assessment of its binding towards 33 normal human organs was performed as well. Rebmab200 showed selected strong reactivity with the tested tumor types but little or no reactivity with the normal tissues tested confirming its potential for targeted therapeutics strategies. The remarkable cytotoxicity shown by Rebmab200 in OVCAR-3 cells is a significant addition to the traits of stability and productivity displayed by the top clones of Rebmab200. Antibody-dependent cell-mediated toxicity functionality was confirmed in repeated assays using cancer cell lines derived from ovary, kidney and lung as targets. To explore use of this antibody in clinical trials, GMP production of Rebmab200 has been initiated. As the next step of development, Phase I clinical trials are now planned for translation of Rebmab200 into the clinic.
Collapse
MESH Headings
- Animals
- Antibodies, Monoclonal/immunology
- Antibodies, Monoclonal/pharmacology
- Antibodies, Monoclonal, Humanized/genetics
- Antibodies, Monoclonal, Humanized/immunology
- Antibodies, Monoclonal, Humanized/pharmacology
- Antibody Specificity/immunology
- Antibody-Dependent Cell Cytotoxicity/drug effects
- Antibody-Dependent Cell Cytotoxicity/immunology
- Cell Line, Tumor
- Cell Survival/drug effects
- Cell Survival/immunology
- Complement System Proteins/immunology
- Female
- Flow Cytometry
- Humans
- Immunohistochemistry
- Kinetics
- Mice
- Neoplasms/drug therapy
- Neoplasms/immunology
- Neoplasms/pathology
- Ovarian Neoplasms/drug therapy
- Ovarian Neoplasms/immunology
- Ovarian Neoplasms/pathology
- Protein Binding/immunology
- Sodium-Phosphate Cotransporter Proteins, Type IIb/antagonists & inhibitors
- Sodium-Phosphate Cotransporter Proteins, Type IIb/immunology
- Surface Plasmon Resonance
Collapse
Affiliation(s)
- Mariana Lopes dos Santos
- Lab. de Biofármacos em Células Animais, Instituto Butantan, São Paulo, Brazil
- Recepta Biopharma, São Paulo, Brazil
| | - Fernanda Perez Yeda
- Lab. de Biofármacos em Células Animais, Instituto Butantan, São Paulo, Brazil
- Recepta Biopharma, São Paulo, Brazil
| | - Lilian Rumi Tsuruta
- Lab. de Biofármacos em Células Animais, Instituto Butantan, São Paulo, Brazil
- Recepta Biopharma, São Paulo, Brazil
| | - Bruno Brasil Horta
- Lab. de Biofármacos em Células Animais, Instituto Butantan, São Paulo, Brazil
- Recepta Biopharma, São Paulo, Brazil
| | - Alécio A. Pimenta
- Lab. de Biofármacos em Células Animais, Instituto Butantan, São Paulo, Brazil
- Recepta Biopharma, São Paulo, Brazil
| | - Theri Leica Degaki
- Lab. de Biofármacos em Células Animais, Instituto Butantan, São Paulo, Brazil
- Recepta Biopharma, São Paulo, Brazil
| | - Ibere C. Soares
- Recepta Biopharma, São Paulo, Brazil
- LIM14-Depto. de Patologia, Faculdade de Medicina, Universidade de São Paulo, São Paulo, Brazil
| | | | - Oswaldo Keith Okamoto
- Recepta Biopharma, São Paulo, Brazil
- Depto. de Genética e Biologia Evolutiva, Instituto de Biociências, Universidade de São Paulo, São Paulo, Brazil
| | - Venancio A. F. Alves
- Recepta Biopharma, São Paulo, Brazil
- LIM14-Depto. de Patologia, Faculdade de Medicina, Universidade de São Paulo, São Paulo, Brazil
| | - Lloyd J. Old
- Ludwig Institute for Cancer Research, New York Branch at Memorial Sloan-Kettering Cancer Center, New York, United States of America
| | - Gerd Ritter
- Ludwig Institute for Cancer Research, New York Branch at Memorial Sloan-Kettering Cancer Center, New York, United States of America
| | - Ana Maria Moro
- Lab. de Biofármacos em Células Animais, Instituto Butantan, São Paulo, Brazil
- * E-mail:
| |
Collapse
|
28
|
Fernández-García JP, Cubero M, Rodríguez-Gallardo M, Acosta L, Alcorta M, Alvarez MAG, Borge MJG, Buchmann L, Diget CA, Falou HA, Fulton BR, Fynbo HOU, Galaviz D, Gómez-Camacho J, Kanungo R, Lay JA, Madurga M, Martel I, Moro AM, Mukha I, Nilsson T, Sánchez-Benítez AM, Shotter A, Tengblad O, Walden P. 11Li Breakup on 208 at energies around the Coulomb barrier. Phys Rev Lett 2013; 110:142701. [PMID: 25166983 DOI: 10.1103/physrevlett.110.142701] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 10/08/2012] [Revised: 12/22/2012] [Indexed: 06/03/2023]
Abstract
The inclusive breakup for the (11)Li + (208)Pb reaction at energies around the Coulomb barrier has been measured for the first time. A sizable yield of (9)Li following the (11)Li dissociation has been observed, even at energies well below the Coulomb barrier. Using the first-order semiclassical perturbation theory of Coulomb excitation it is shown that the breakup probability data measured at small angles can be used to extract effective breakup energy as well as the slope of B(E1) distribution close to the threshold. Four-body continuum-discretized coupled-channels calculations, including both nuclear and Coulomb couplings between the target and projectile to all orders, reproduce the measured inclusive breakup cross sections and support the presence of a dipole resonance in the (11)Li continuum at low excitation energy.
Collapse
Affiliation(s)
- J P Fernández-García
- Departamento de FAMN, Universidad de Sevilla, Apartado 1065, E-41080 Seville, Spain and Centro Nacional de Aceleradores, Universidad de Sevilla/Junta de Andalucía/CSIC, E-41092 Seville, Spain
| | - M Cubero
- Instituto de Estructura de la Materia-CSIC, E-28006 Madrid, Spain and Centro de Investigación en Ciencias Atómicas, Nucleares y Moleculares (CICANUM), CR-2060 San José, Costa Rica
| | - M Rodríguez-Gallardo
- Departamento de FAMN, Universidad de Sevilla, Apartado 1065, E-41080 Seville, Spain
| | - L Acosta
- Istituto Nazionali di Fisica Nucleare-Laboratori Nazionali del Sud (INFN-LNS), I-95123 Catania, Italy and Departamento de Física Aplicada, Universidad de Huelva, E-21071 Huelva, Spain
| | - M Alcorta
- Instituto de Estructura de la Materia-CSIC, E-28006 Madrid, Spain
| | - M A G Alvarez
- Departamento de FAMN, Universidad de Sevilla, Apartado 1065, E-41080 Seville, Spain and Centro Nacional de Aceleradores, Universidad de Sevilla/Junta de Andalucía/CSIC, E-41092 Seville, Spain
| | - M J G Borge
- Instituto de Estructura de la Materia-CSIC, E-28006 Madrid, Spain
| | - L Buchmann
- TRIUMF, Vancouver, British Columbia V-6T2A3, Canada
| | - C A Diget
- Departament of Physics, University of York, YO1O-5DD Heslington, York, United Kingdom
| | - H A Falou
- Department of Astronomy and Physics, Saint Mary's University, Halifax B3H3C3, Canada
| | - B R Fulton
- Departament of Physics, University of York, YO1O-5DD Heslington, York, United Kingdom
| | - H O U Fynbo
- Department of Physics and Astronomy, Aarhus University, DK-8000 Aarhus, Denmark
| | - D Galaviz
- Centro de Física Nuclear da Universidade de Lisboa (CFNUL), 1649-003 Lisbon, Portugal
| | - J Gómez-Camacho
- Departamento de FAMN, Universidad de Sevilla, Apartado 1065, E-41080 Seville, Spain and Centro Nacional de Aceleradores, Universidad de Sevilla/Junta de Andalucía/CSIC, E-41092 Seville, Spain
| | - R Kanungo
- Department of Astronomy and Physics, Saint Mary's University, Halifax B3H3C3, Canada
| | - J A Lay
- Departamento de FAMN, Universidad de Sevilla, Apartado 1065, E-41080 Seville, Spain
| | - M Madurga
- Instituto de Estructura de la Materia-CSIC, E-28006 Madrid, Spain
| | - I Martel
- Departamento de Física Aplicada, Universidad de Huelva, E-21071 Huelva, Spain
| | - A M Moro
- Departamento de FAMN, Universidad de Sevilla, Apartado 1065, E-41080 Seville, Spain
| | - I Mukha
- Departamento de FAMN, Universidad de Sevilla, Apartado 1065, E-41080 Seville, Spain
| | - T Nilsson
- Fundamental Physics, Chalmers University of Technology, S-41296 Göteborg, Sweden
| | - A M Sánchez-Benítez
- Departamento de Física Aplicada, Universidad de Huelva, E-21071 Huelva, Spain
| | - A Shotter
- School of Physics and Astronomy, University of Edinburgh, EH9 3JZ Edinburgh, United Kingdom
| | - O Tengblad
- Instituto de Estructura de la Materia-CSIC, E-28006 Madrid, Spain
| | - P Walden
- TRIUMF, Vancouver, British Columbia V-6T2A3, Canada
| |
Collapse
|
29
|
|
30
|
Cubero M, Fernández-García JP, Rodríguez-Gallardo M, Acosta L, Alcorta M, Alvarez MAG, Borge MJG, Buchmann L, Diget CA, Al Falou H, Fulton BR, Fynbo HOU, Galaviz D, Gómez-Camacho J, Kanungo R, Lay JA, Madurga M, Martel I, Moro AM, Mukha I, Nilsson T, Sánchez-Benítez AM, Shotter A, Tengblad O, Walden P. Do halo nuclei follow Rutherford elastic scattering at energies below the barrier? The case of 11Li. Phys Rev Lett 2012; 109:262701. [PMID: 23368554 DOI: 10.1103/physrevlett.109.262701] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 10/07/2012] [Indexed: 06/01/2023]
Abstract
The first measurement of the elastic scattering of the halo nucleus 11Li and its core 9Li on 208Pb at energies near the Coulomb barrier is presented. The 11Li+208Pb elastic scattering shows a strong reduction with respect to the Rutherford cross section, even at energies well below the barrier and down to very small scattering angles. This drastic change of the elastic differential cross section observed in 11Li+208Pb is the consequence of the halo structure of 11Li, as it is not observed in the elastic scattering of its core 9Li at the same energies. Four-body continuum-discretized coupled-channels calculations, based on a three-body model of the 11Li projectile, are found to explain the measured angular distributions and confirm that the observed reduction is mainly due to the strong Coulomb coupling to the dipole states in the low-lying continuum of 11Li. These calculations suggest the presence of a low-lying dipole resonance in 11Li close to the breakup threshold.
Collapse
Affiliation(s)
- M Cubero
- Instituto de Estructura de la Materia CSIC, E28006 Madrid, Spain
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
31
|
Moro AM, Lay JA. Interplay between valence and core excitation mechanisms in the breakup of halo nuclei. Phys Rev Lett 2012; 109:232502. [PMID: 23368187 DOI: 10.1103/physrevlett.109.232502] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 07/27/2012] [Revised: 10/20/2012] [Indexed: 06/01/2023]
Abstract
The phenomenon of core excitation in the breakup of a two-body halo nucleus is investigated. We show that this effect plays a significant role in the reaction dynamics and, furthermore, its interference with the valence excitation mechanism has sizable and measurable effects on the breakup angular distributions. These effects have been studied in the resonant breakup of (11)Be on a carbon target, populating the resonances at 1.78 MeV (5/2(+)) and 3.41 MeV (3/2(+)). The calculations have been performed using a recent extension of the distorted-wave Born approximation method, which takes into account the effect of core excitation in both the structure of the halo nucleus and in the reaction mechanism. The calculated angular distributions have been compared with the available data [Fukuda et al., Phys. Rev. C 70, 054606 (2004).]. Although each of these resonances is dominated by one of the two considered mechanisms, the angular patterns of these resonances depend in a very delicate way on the interference between them. This is the first clear evidence of this effect but the phenomenon is likely to occur in other similar reactions.
Collapse
Affiliation(s)
- A M Moro
- Departamento de FAMN, Universidad de Sevilla, Apartado 1065, E-41080 Sevilla, Spain.
| | | |
Collapse
|
32
|
Marón LB, Covas CP, da Silveira NP, Pohlmann A, Mertins O, Tatsuo LN, Sant´Anna OAB, Moro AM, Takata CS, de Araujo PS, Bueno da Costa MH. LUVs Recovered with Chitosan: A New Preparation for Vaccine Delivery. J Liposome Res 2008; 17:155-63. [DOI: 10.1080/01460860701525444] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|
33
|
Augusti PR, Conterato GMM, Somacal S, Sobieski R, Spohr PR, Torres JV, Charão MF, Moro AM, Rocha MP, Garcia SC, Emanuelli T. Effect of astaxanthin on kidney function impairment and oxidative stress induced by mercuric chloride in rats. Food Chem Toxicol 2008; 46:212-9. [PMID: 17881112 DOI: 10.1016/j.fct.2007.08.001] [Citation(s) in RCA: 52] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/03/2007] [Revised: 07/21/2007] [Accepted: 08/01/2007] [Indexed: 11/18/2022]
Abstract
Reactive oxygen species are implicated as mediators of tissue damage in the acute renal failure induced by inorganic mercury. Astaxanthin (ASX), a carotenoid with potent antioxidant properties, exists naturally in various plants, algae, and seafoods. This paper evaluated the ability of ASX to prevent HgCl(2) nephrotoxicity. Rats were injected with HgCl(2) (0 or 5 mg/kg b.w., sc) 6h after ASX had been administered (0, 10, 25, or 50mg/kg, by gavage) and were killed 12h after HgCl(2) exposure. Although ASX prevented the increase of lipid and protein oxidation and attenuated histopathological changes caused by HgCl(2) in kidney, it did not prevent creatinine increase in plasma and delta-aminolevulinic acid dehydratase inhibition induced by HgCl(2). Glutathione peroxidase and catalase activities were enhanced, while superoxide dismutase activity was depressed in HgCl(2)-treated rats when compared to control and these effects were prevented by ASX. Our results indicate that ASX could have a beneficial role against HgCl(2) toxicity by preventing lipid and protein oxidation, changes in the activity of antioxidant enzymes and histopathological changes.
Collapse
Affiliation(s)
- P R Augusti
- Post-graduate Program on Toxicological Biochemistry, Center of Natural and Exact Sciences, Federal University of Santa Maria, 97105-900 Santa Maria, RS, Brazil
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
34
|
Puchalski M, Moro AM, Pachucki K. Isotope shift of the 32S 1/2 -22S 1/2 transition in lithium and the nuclear polarizability. Phys Rev Lett 2006; 97:133001. [PMID: 17026029 DOI: 10.1103/physrevlett.97.133001] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 07/29/2006] [Indexed: 05/12/2023]
Abstract
High precision calculation of the isotope shift of the 3(2)S(1/2)-2(2)S(1/2) transition in lithium is presented. The wave function and matrix elements of relativistic operators are obtained by using recursion relations. Apart from the relativistic contribution, we obtain the nuclear polarizability correction for 11Li. The resulting difference of the squared charge radii 11Li-7Li based on the measurements of Sánchez et al. [Phys. Rev. Lett. 96, 033002 (2006)10.1103/PhysRevLett.96.033002] is deltar(ch)(2)=0.157(81) fm(2), which significantly differs from the previous evaluation.
Collapse
Affiliation(s)
- M Puchalski
- Institute of Theoretical Physics, Warsaw University, Hoza 69, 00-681 Warsaw, Poland
| | | | | |
Collapse
|
35
|
Grotto D, Santa Maria LD, Boeira S, Valentini J, Charão MF, Moro AM, Nascimento PC, Pomblum VJ, Garcia SC. Rapid quantification of malondialdehyde in plasma by high performance liquid chromatography-visible detection. J Pharm Biomed Anal 2006; 43:619-24. [PMID: 16949242 DOI: 10.1016/j.jpba.2006.07.030] [Citation(s) in RCA: 239] [Impact Index Per Article: 13.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/09/2006] [Revised: 07/11/2006] [Accepted: 07/13/2006] [Indexed: 11/21/2022]
Abstract
BACKGROUND Malondialdehyde (MDA) is one of the better-known secondary products of lipid peroxidation, and it is widely used as an indicator of cellular injury. The employment of the thiobarbituric acid reactive substances (TBARS) technique to measure MDA has received criticism over the years because of its lack of specificity. Thus, a specific and reliable method for MDA determination in plasma by high performance liquid chromatographic (HPLC)-VIS was validated; alkaline hydrolysis, n-butanol extraction steps and MDA stability were established. METHODS The plasma underwent alkaline hydrolysis, acid deproteinization, derivatization with TBA and n-butanol extraction. After this, MDA was determined at 532 nm by HPLC-VIS. The method was applied to 65-year-old subjects from a retirement home. RESULTS The assay was linear from 0.28 to 6.6 microM. The reproducibility of intra-run was obtained with CV%<4% and the inter run with CV%<11%. The accuracy (bias) ranged from 2 to -4.1%, and the recovery was greater than 95%. The limit of detection (LOD) and limit of quantification (LOQ) were 0.05 and 0.17 microM, respectively. For the stability test, every sample was stored at -20 degrees C. The plasma MDA was not stable when stored after the alkaline hydrolysis step, remained stable for 30 days after TBA derivatization storage and was stable for 3 days when stored after n-butanol extraction. The elderly subjects had MDA plasma levels of 4.45+/-0.81 microM for women and 4.60+/-0.95 microM for men. CONCLUSION The method is reproducible, accurate, stable, sensitive, and can be used in the routines in clinical laboratories. Besides, this technique presents advantages such as the complete release of protein bound MDA with the alkaline hydrolysis step, the removal of interferents with n-butanol extraction, mobile phase without phosphate buffer and rapid analytical processes and run times.
Collapse
Affiliation(s)
- D Grotto
- Department of Clinical and Toxicological Analysis, Federal University of Santa Maria, Santa Maria, C.P. 5061, Campus Universitário, 97110-970 RS, Brazil
| | | | | | | | | | | | | | | | | |
Collapse
|
36
|
Caldas C, Coelho V, Kalil J, Moro AM, Maranhão AQ, Brígido MM. Humanization of the anti-CD18 antibody 6.7: an unexpected effect of a framework residue in binding to antigen. Mol Immunol 2003; 39:941-52. [PMID: 12695120 DOI: 10.1016/s0161-5890(03)00022-1] [Citation(s) in RCA: 19] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
Abstract
Humanization of monoclonal antibodies by complementary determinant region (CDR)-grafting has become a standard procedure to improve the clinical usage of animal antibodies. However, antibody humanization may result in loss of activity that has been attributed to structural constraints in the framework structure. In this paper, we report the complete humanization of the 6.7 anti-human CD18 monoclonal antibody in a scFv form. We used a germline-based approach to design a humanized VL gene fragment and expressed it together with a previously described humanized VH. The designed humanized VL has only 14 mutations compared to the closest human germline sequence. The resulting humanized scFv maintained the binding capacity and specificity to human CD18 expressed on the cell surface of peripheral blood mononuclear cells (PBMC), and showed the same pattern of staining T-lymphocytes sub-populations, in comparison to the original monoclonal antibody. We observed an unexpected effect of a conserved mouse-human framework position (L37) that hinders the binding of the humanized scFv to antigen. This paper reveals a new framework residue that interferes with paratope and antigen binding and also reinforces the germline approach as a successful strategy to humanize antibodies.
Collapse
Affiliation(s)
- Cristina Caldas
- Departamento de Biologia Celular, Universidade de Brasi;lia, 70910-900, DF, Brasília, Brazil.
| | | | | | | | | | | |
Collapse
|
37
|
Caldas C, Coelho VP, Rigden DJ, Neschich G, Moro AM, Brígido MM. Design and synthesis of germline-based hemi-humanized single-chain Fv against the CD18 surface antigen. Protein Eng 2000; 13:353-60. [PMID: 10835109 DOI: 10.1093/protein/13.5.353] [Citation(s) in RCA: 20] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/14/2022]
Abstract
The 6.7 murine monoclonal antibody (mAb) recognizes the human CD18 antigen and is therefore of interest as an anti-inflammatory agent. The 6.7 heavy variable chain (VH) was humanized using the closest human germline sequence as the template on to which to graft the murine complementary determining regions (CDRs). Two versions were proposed, one in which the residue proline 45 of the murine form was maintained and another in which this framework residue was changed to the leucine found in the human sequence. These VH humanized versions were expressed in the yeast Pichia pastoris as hemi-humanized single-chain Fv (scFvs), with the VL from the murine antibody. The scFv from the murine antibody was also expressed. The binding activities of the murine and both hemi-humanized scFvs were determined by flow cytometry analysis. All the constructions were able to recognize human lymphocytes harboring CD18, indicating successful humanization with transfer of the original binding capability. Some differences between the two hemi-humanized versions were observed. The method used was simple and straightforward, with no need for refined structural analyses and could be used for the humanization of other antibodies.
Collapse
Affiliation(s)
- C Caldas
- Departamento de Biologia Celular, Universidade de Bras¿ilia, Bras¿ilia, DF, 70910-900, Laborat¿orio de Imunologia de Transplantes, INCOR/Universidade de Såo Paulo, Såo Paulo, SP, Brazil
| | | | | | | | | | | |
Collapse
|
38
|
Davico Bonino L, De Monte LB, Spagnoli GC, Vola R, Mariani M, Barone D, Moro AM, Riva P, Nicotra MR, Natali PG. Bispecific monoclonal antibody anti-CD3 x anti-tenascin: an immunotherapeutic agent for human glioma. Int J Cancer 1995; 61:509-15. [PMID: 7538978 DOI: 10.1002/ijc.2910610414] [Citation(s) in RCA: 20] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/25/2023]
Abstract
Besides surgery, the therapeutic possibilities for the treatment of human gliomas include adoptive cellular immunotherapy, radioimmunotherapy, immunotherapy mediated by chemoimmunoconjugates and, more recently, bispecific monoclonal antibodies (biMAbs). Anti-CD3 x anti-tenascin (TN) is the first reagent of a number of biMAbs under investigation for prospective use in vivo to maximize the cell-mediated cytolytic potential of glioma patients. This biMAb originated from the fusion of 2 parental hybridomas, made resistant by retrovirus-mediated infection to the different metabolic drugs, geneticin and methotrexate, respectively. The resulting hybrid hybridomas were selected on the basis of the double specificity for CD3 and TN, cloned several times and grown under continuous metabolic pressure. The different families of recombinant antibodies were then purified by high-pressure liquid chromatography on hydroxylapatite columns. Immunohistochemical studies on tumor specimens of different origin and histotype have shown that the selected biMAb presented a distribution pattern similar to that of the parental anti-TN MAb, maintaining the same staining homogeneity and intensity. Moreover, the mitogenic activity of anti-CD3 x anti-TN biMAb on peripheral blood mononuclear cells was similar to that featured by the parental anti-CD3 MAb. Furthermore, the hybrid molecule induced TNF-alpha gene expression in activated PBMC. Finally, the anti-CD3 x anti-TN featured the desired killer targeting ability, being able to induce a significantly increased cytotoxic activity against TN+ tumor cells.
Collapse
Affiliation(s)
- L Davico Bonino
- Dipartimento di Genetica, Biologia e Chimica Medica, Università di Torino, Turin, Italy
| | | | | | | | | | | | | | | | | | | |
Collapse
|
39
|
Moro AM, Rodrigues MT, Gouvea MN, Silvestri ML, Kalil JE, Raw I. Multiparametric analyses of hybridoma growth on glass cylinders in a packed-bed bioreactor system with internal aeration. Serum-supplemented and serum-free media comparison for MAb production. J Immunol Methods 1994; 176:67-77. [PMID: 7963595 DOI: 10.1016/0022-1759(94)90351-4] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/28/2023]
Abstract
Monoclonal antibodies are one of the most important products of biotechnology and laboratories and companies all over the world are pursuing their large-scale production. Herein we report a protocol for hybridoma cell cultivation over small glass cylinders inside a 3 liter bioreactor vessel which leads to the production and purification--in order of grams--of one MAb intended for human therapeutic use. This protocol proved to be simple, reproducible and cost effective. Three trials are reported: the first two using conventionally serum-supplemented medium culture and producing 3.15 and 2.1 g of purified MAb in 30 and 21 days respectively, and the third one using serum-free medium culture and producing 6 g of purified MAb in 36 days. We have ascertained the stability of the hybridoma by its cloning directly in serum-free medium. The downstream processing of the serum-free trial was done in a single step, concentrating large volumes of supernatant while simultaneously purifying the antibody.
Collapse
Affiliation(s)
- A M Moro
- Centro de Biotecnologia, Instituto Butantan, Sao Paulo, Brazil
| | | | | | | | | | | |
Collapse
|
40
|
Frota-Pessoa O, Ferreira NR, Pedroso MB, Moro AM, Otto PA, Chamone DA, Da Silva LC. A study of chromosomes of lymphocytes from patients treated with hycanthone. J Toxicol Environ Health 1975; 1:305-7. [PMID: 1206772 DOI: 10.1080/15287397509529330] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/26/2022]
Abstract
The frequency of cells presenting chromosome abnormalities was determined in patients with schistosomiasis before and after treatment with a single dose of 2.5 mg/kg body weight of hycanthone methanosulfonate. No significant effect of the drug was detected with this therapeutic dose.
Collapse
|